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The broad theme of this thesis is the development of CRISPR-based genetic engineering technology, 
primarily focusing on an exploration of mammalian gene drives.  
The CRISPR/Cas9 system utilises a complex composed of the Cas9 nuclease for DNA cleavage and a 
guide RNA (gRNA) for targeting it to a specific genomic locus. Since its revolutionary discovery and 
utilisation as a genome editing tool, one pioneering application is the CRISPR-based gene drive: The 
insertion of the genes for both Cas9 and the gRNA into a specific chromosome in an animal such that 
the gRNA targets the homologous locus of the wild type (WT) chromosome. In the offspring of a 
cross with a WT animal, the gene drive is initially hemizygous. Subsequently the nuclease and gRNA 
complex together and cleave the WT chromosome, resulting in copying of the nuclease and gRNA 
genes into that WT chromosome via homology-directed repair (HDR), termed “homing” in the 
context of gene drives. When viewed at a population level, this results in the rapid spread of the 
gene drive throughout a wild population. 
Due to this “Super-Mendelian” inheritance, a gene drive offers the potential to modify entire wild 
populations. This opens numerous possibilities such as the eradication or suppression of populations 
of invasive pests or immunising natural populations against human pathogens such as malaria in 
mosquitoes. These are extremely powerful outcomes that could reduce human disease burden, 
reverse the devastating impact of invasive pests on ecosystems, or greatly reduce the agricultural 
cost of dealing with pests. 
Gene drives have been experimentally tested in a small number of species including the fly 
Drosophila melanogaster, the yeast Saccharomyces cerevisiae, and the three mosquito species 
Anopheles stephensi, Anopheles gambiae, and Aedes aegypti. All of these have had a very high 
homing rate. A low rate of homing has also been observed in Mus musculus in the female germline 
but otherwise no vertebrates have experimentally developed gene drives. 
This thesis describes the generation of four experimental gene drive approaches in mice, two of 
which used Cas9 as the nuclease under the control of either zygotic (CAG) or germline (Vasa) 
promoters, and another two that used Cas12a with either zygotic (CMV) or germline (Vasa) 
promoters. Gene drives were constructed with the key safety features of a “split drive” and a 
“synthetic target” to avoid any ecological impact in case of accidental release. 
Homing did not occur at any detectable rate in any of the gene drives. Both the Cas9 zygotic-homing 
gene drive and the germline-homing gene drive in males showed a high percentage of indels at the 
synthetic target, indicating a high rate of Cas9-induced cleavage. It was concluded that zygotic-
homing likely failed to occur due to lack of proximity between the gene drive chromosome and the 
synthetic target chromosome, as they remain separated a full 18-20 hours post-fertilisation until 
after the first G2 phase. 
Germline-homing likely didn’t occur in the males as Vasa-induced expression begins during a period 
of mitotic proliferation of the primordial germ cells, a cellular state that likely doesn’t promote the 
HDR required for homing. Contrasting this, the female oocytes are undergoing meiosis at this time 
point, where the homologous chromosomes are aligned and in an ideal position to promote HDR. 
However, Cas9 expression levels in the female germline were very low and likely reduced the 
chances of any homing occurring. 
The Cas12a gene drives all failed to generate an appreciable level of Cas12a cleavage (0-4.3% across 




mouse models used to test the Cas12a gene drive here were not sufficient to accurately assess its 
functionality. 
This thesis also discusses the design and testing of a suite of all-in-one CRISPR gene editing plasmids 
that allowed one-step generation of said plasmids containing two unique, customisable gRNAs. 
These were all successfully made and showed consistent, simultaneous cleavage of multiple target 
sites within cell culture, allowing for multiple knockdowns, large deletions, or reduction of off-target 
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6.1 CRISPR TECHNOLOGY 
6.1.1 Terminology 
Generically, the term “CRISPR” (clustered regularly interspaced short palindromic repeats) refers to 
both the use of and the suite of genome editing and related molecular tools that are composed of 
CRISPR associated (Cas) proteins and the short RNA molecules that bind to them. Technically and 
historically, the term was only used to refer to a class of DNA repeats in prokaryotes which the 
above-mentioned RNA is derived from and function as part of an acquired immune system for 
prokaryotes.1-3 In the context of this thesis, “CRISPR”, “CRISPR-based”, etc. will refer to the genome 
editing tools. 
Homology-directed repair (HDR) is a term that encompasses several different DNA repair pathways, 
most of which utilise donor DNA as a template, and are discussed in section 6.1.7 in further detail.4 
Homologous recombination (HR) is a specific HDR pathway4 which is often used in the literature 
interchangeably with HDR to mean all of the HDR pathways. 
6.1.2 Origins 
The first CRISPR system that was developed for genome editing applications utilised SpCas9, derived 
from Streptococcus pyogenes.3 This provided a programmable and easy-to-use system for inducing 
double-stranded breaks (DSBs) in DNA for the purposes of creating targeted small insertions or 
deletions (indels) or inserting custom DNA sequences at specific genomic loci.3, 5 
6.1.3 Components 
The CRISPR/Cas9 system is composed of the nuclease Cas9 and an associated gRNA – a short, single-
stranded RNA molecule (Figure 1).3 When both are present in a cell’s nucleus, Cas9 initially binds to 
the gRNA which induces conformational changes in Cas9 to allow it to bind to genomic DNA.3, 6 This 
ribonucleoprotein (RNP) complex is able to target a specific genomic position by two different 
elements: Firstly, Cas9 recognises a protospacer adjacent motif (PAM) on the non-complementary 
DNA strand (composed of the sequence NGG for SpCas9).3, 7 Secondly, the ∼20 bp “guide” sequence 
at the 5’ end of the gRNA binds to the complementary gRNA binding site on the DNA.3, 6 Double-
stranded DNA cleavage then occurs 3 bp upstream of the PAM by the Cas9 HNH nuclease and RuvC-
like domains.3 
  
Figure 1. Schematic of CRISPR/Cas9 system. Cas9 protein (teal) is bound to a gRNA (red) and genomic DNA (grey).3, 6 The 
PAM, with sequence NGG (green), is bound to the protein, and the gRNA binding site (blue) is bound to the ∼20 bp guide 




6.1.4 Targeting Efficiency and Specificity 
The efficiency of a particular guide to induce cleavage is influenced by a number of different factors 
including the epigenetic landscape of the target site and the composition of the guide itself.9, 10 
Guide composition can cause reduced or early termination of gRNA transcription, secondary 
structure formation which interferes with Cas9/DNA binding, or have inefficiencies due to unknown 
mechanisms.9, 10 Ultimately the efficiency of a guide can only be experimentally determined but 
there are bioinformatic processes that have been developed to predict the efficiency.9, 10 
Another consideration when designing guides is whether or not they will generate DSBs at 
unintended genomic sites (off-target cleavage). A basic local alignment search tool (BLAST) analysis 
of the sequence will ensure there aren’t any identical off-target gRNA binding sites adjacent to 
PAMs.11 It is more complex than this however, as there is a complicated relationship between the 
guide sequence and potential off-target sites that have one or more base-pair mismatches (MMs). It 
has been shown that the more MMs there are in an off-target site the less likely it will be cut. It has 
also been shown that off-target sites with MMs near the PAM are least likely to be cut, whereas sites 
with MMs further away from the PAM are most likely to be cut.12-14 It is further complicated by 
whether there are multiple MMs next to each other and what the specific bases are but these details 
are yet to be completely understood.12-14 In addition to this, Cas9 has been shown to have a very low 
level of activity with an NAG PAM site instead of NGG.14 
In the case where there are potential off-target sites that may be cut, it is prudent to look at each 
specific genomic locus and determine if indels at that location would be deleterious or not. 
Oftentimes the sites will be intergenic or intronic and thus unlikely to affect the cell or organism’s 
viability. There are now multiple tools available online that can perform most of the analyses 
described above including the initial design of the guide and assessing its potential cutting efficiency. 
The tools used throughout this thesis were CCTop (https://crispr.cos.uni-heidelberg.de/)15, GT-Scan 
(https://gt-scan.csiro.au/)16, Benchling (https://benchling.com/)17, and the now-decommissioned 
Zhang lab tool (formerly at http://crispr.mit.edu/)14. 
6.1.5 Methodology 
There are two primary uses for the generation of a DSB with CRISPR. The first is to induce the 
formation of a random, small indel via the cell’s error-prone repair pathways (see section 6.1.7). This 
can disrupt a critical amino acid in a gene or cause frameshift mutations, both potentially leading to 
loss-of-function. The second is to provide a site for the insertion of custom donor DNA (see section 
6.1.6) to generate gene knock-in models, tags, conditional alleles, and many other modifications. 
For the generation of a mouse model, gRNA and Cas9 (protein or mRNA) can be delivered to 
cultured zygotes via microinjection, which are then transferred into pseudopregnant females and 
allowed to come to term (Figure 2).18 Typically multiple different indels will be generated which can 
be easily separated by outcrossing to WT mice.18 An added benefit of outcrossing to WT mice is that 
off-target mutations will be segregated away from the desired mutants at the same time, assuming 




Figure 2. Examples of CRISPR/Cas9 delivery techniques and applications. Left shows delivery of a Cas9 protein pre-loaded 
with a gRNA into a mouse zygote via microinjection.18 Right shows delivery of a CRISPR plasmid to cells via transfection, the 
plasmid(s) encode genes for both the Cas9 protein and the gRNA so the cells themselves will express them.19, 20 Image 
created with BioRender.8 
For cell work, CRISPR components can be delivered in a variety of ways. Most notably are all-in-one 
plasmids which contain a Cas9 gene under a suitable promoter (e.g. the cytomegalovirus (CMV) 
promoter for ubiquitous expression), a gRNA scaffold that allows easy cloning in of a guide (also 
under a suitable promoter such as U6), and a variety of different selectable markers.19-21 These can 
be delivered to cells through typical methods such as transfection or infection.22, 23 Once in the cells, 
Cas9 and the gRNA are expressed, allowing formation of the RNP complex and subsequent DNA 
cleavage, repair, and indel formation.12 
6.1.6 Transgenics 
As mentioned above, the other basic application of CRISPR is the ability to generate transgenic mice 
with the addition of donor DNA once a DSB has been generated. Technically, this is a separate 
technique from CRISPR, but the ease of which targeted DNA cleavage can now be accomplished with 
CRISPR has strongly tied the two together. Older methods to generate transgenic animal models 
such as gene targeting by homologous recombination could not be performed in zygotes.24 For 
rodents it relied on very rare integration events in embryonic stem cells (1 in 106-109 cells) which 
then had to be transferred to blastocyst embryos to generate chimeras. Breeding of chimeras was 
then used to transmit the mutation to the next generation (a process that did not always occur). 
Typically, generation of mutant a mouse using ES cells took around a year but can now be 
accomplished with CRISPR in a few weeks.24 
The basic concept is illustrated in Figure 3A where donor DNA in various forms can be delivered to 
living cells along with the CRISPR components. Whether it is linear double-stranded DNA (dsDNA), 
single-stranded DNA (ssDNA)25 or circular plasmid DNA, all 3 contain the transgene of interest 
flanked by homology arms that are identical in sequence to either side of the CRISPR cut site.5, 26 
Whether these are delivered to cells in culture, zygotes, or specific animal tissues, the outcome is 
the same as per Figure 3B, in that the cell’s HDR pathways can integrate the transgene into the same 





Figure 3. (A) Schematic showing different methods of custom DNA insertion. A custom DNA sequence (orange), flanked by 
homology arms (blue) which have identical sequence to the genomic regions flanking the CRISPR cut site.5, 26 (B) After the 
genomic DNA is cut, the homology arms are utilised by the cell’s HDR pathways and the custom DNA is inserted into the cut 
site.5 Image created with BioRender.8 
6.1.7 DNA Repair Outcomes 
Transgene integration as depicted in Figure 3B occurs via HDR, which includes several different 
cellular pathways.27 Although it is the desired outcome, it typically occurs at very low efficiency.5 
There are a handful of other pathways that predominate and they all lead to the generation of indels 
at the target site.28 This includes non-homologous end-joining (NHEJ),29 microhomology-mediated 
end-joining (MMEJ), also called alternative end-joining,30 and single-strand annealing (SSA).31 
Although the latter is technically a type of HDR, it also leads to the generation of indels.31 
The factors that determine the repair pathways and how exactly they function are not fully 
understood.28 An overview of these pathways is shown in Figure 4, the major decision point between 
NHEJ and all other pathways occurs after the initial processing of the free DNA ends when a DSB is 
generated.28 If the activity of specific 5’ to 3’ exonucleases proceeds on the DNA ends, termed 
17 
 
“resectioning” which leaves 3’ overhangs on the DNA, then the non-NHEJ pathways take control. 
And if this does not occur, then NHEJ proceeds.28 
 
Figure 4. Schematic of major DNA repair pathways. DNA with a DSB shown at top, leading to the repaired DNA at the 
bottom. Image modified from Chang et al. (2017). 
A couple of the reasons why NHEJ is favoured are that it is active in all phases of the cell cycle,4 and 
it occurs more quickly than HDR,4 completely repairing the DSB in as little as 30 minutes.32 Initiation 
of NHEJ occurs as any free DNA ends are quickly bound by the Ku70–Ku80 complex (Ku)33 which 
recruits a suite of nucleases, polymerases, ligases, and other proteins to catalyse NHEJ.28 Although 
short resectioning can occur (<20 bp) with Ku bound,28 it otherwise inhibits longer resectioning and 
thus inhibits HDR and MMEJ.4 Enzymatic action at each end of the different DNA ends happens 
sequentially and can consist of a nuclease removing nucleotides, a polymerase adding nucleotides, 
or a ligase joining the ends together.28 For an individual DSB, multiple rounds of each of these 
activities can occur, a different number of times for each enzyme and in different orders, resulting in 
multiple different indels generated from an identical DSB.28 Although mechanistic details of why 
specific indels are generated from specific DSB events are not known, they can be somewhat reliably 
predicted via machine-learning algorithms employed by software such as inDelphi 
(https://indelphi.giffordlab.mit.edu/).34 
MMEJ is similar to NHEJ in that it is an error-prone repair pathway that doesn’t make use of a DNA 
repair template.30 However, it also shares similarity with HDR in that it requires longer 5’ to 3’ 
resectioning (≥20 bp) to occur.28, 35 Comparatively, the resectioning is a lot shorter than HDR,35 
although the recent demonstration of large deletions (several kb in length) after CRISPR cleavage 
may challenge that assumption.36 With the free 3’ overhangs present on both DNA ends, sections of 
microhomology between those two strands are now exposed, allowing them to anneal together.30 At 
this point, if those microhomologies are present and have annealed, this prevents the HDR pathways 
from going forward.4 After annealing, the MMEJ pathway proceeds, with the end result being the 
loss of all intervening sequence between the microhomologies.30 
Likely a major reason why HDR is much less prolific than other repair pathways is that it is restricted 




longer time in comparison to NHEJ/MMEJ.4 After the initial short-range resectioning with the same 
exonuclease that is active in MMEJ, a separate exonuclease takes over to perform long-range 
resectioning of 1 kb or more.38 At this point there are large sections of homology present between 
the template and the exposed ssDNA that facilitate the HDR process.4 HDR then proceeds through a 
number of different pathways as shown in Figure 5.4 Break-induced replication (BIR) proceeds when 
only one end of the DSB is found.4 For synthesis-dependent strand annealing (SDSA), once a single 
strand is synthesised using the template DNA it dissociates and anneals to the other end of the DSB 
where synthesis of the second strand proceeds without involvement of the template.4 In contrast, 
homologous recombination (HR) causes synthesis of both strands from the template DNA via a 
double Holliday junction, the same process that occurs in crossover during meiosis.4 A key protein 
here is RAD51 which is responsible for the pairing of a repair template to the resectioned DNA and 
leads to BIR, SDSA, and HR.39 
 
Figure 5. Overview of HDR pathways. Left: dsDNA-donor-templated HDR. Right: ssDNA-donor-templated HDR. Image 
modified from Yeh et al. (2019) 
There are also two RAD51-independent HDR pathways that have been characterised,4 SSA (Figure 4) 
is one of these that causes deletions and functions conceptually similarly to MMEJ31 except with 
larger homologies (≥20-200 bp)4. The second RAD51-independent pathway is single-stranded 
templated repair (SSTR) which takes place when a synthetic ssDNA template is supplied.40 A 
proposed repair pathway is shown in Figure 5 but the mechanisms have yet to be elucidated.4 
6.1.8 Expanded CRISPR Toolkit 
Although the CRISPR genome editing applications so far discussed are the most ubiquitously used, 
there is a constantly expanding toolkit making use of CRISPR for a myriad of different functions. 
SpCas9 homologs have been identified from many other species, these have different PAMs (e.g. 
NNGRRT PAM from SaCas9)41 and different cleavage mechanisms (e.g. Cas12a which leaves a 
staggered DSB with 5’ overhangs)42. 
Many modified CRISPR nucleases have also been developed. Two “Nickase” variants of SpCas9 are 
the D10A mutant which inactivates the RuvC nuclease domain3 and the H840A mutant which 
inactivates the HNH nuclease domain19 so that they only induce single-stranded cleavage (“nicking”) 

















































Figure 6. Schematic of DNA modification via prime editing. Top: pegRNA (green) and Nickase (purple) binds target site (blue). 
After the gDNA is nicked, the PBS with adjacent template containing edit (red) binds the ssDNA, and reverse transcriptase 
(RT, brown) extends the ssDNA to incorporate the edit. Bottom: After RT activity, DNA is in a state of equilibrium with a 3’ 
flap containing the edit or a 5’ flap without the edit. After 5’ flap cleavage, DNA is repaired to incorporate the edit. Image 
modified from Anzalone et al. (2019). 
CRISPR applications are not only limited to inducing DNA cleavage however. CRISPR interference 
(CRISPRi) is a technique that uses dCas9.55 When dCas9 is coupled with a gRNA that targets specific 
promoter regions of a gene it will subsequently induce transcriptional repression by blocking the 
activity of RNA polymerase and other transcription factors.55 
dCas9’s intact targeting ability has also been employed to enhance gene expression. To achieve this, 
a virus protein-64 acidic transactivation domain (VP64) was conjugated to the C-terminus of 
dCas9.56, 57 When delivered to cells in combination with gRNAs that target gene-promoter regions, 
they strongly induce expression of that gene.56, 57 Further enhancements have been made to this 
system including conjugation to dCas9 of a tripartite activator composed of a fusion between VP64, 
p65, and the rightward transactivator (Rta) to increase expression by several orders of magnitude 
over a simple dCas9-VP64 fusion protein.58 
6.2 GENE DRIVES 
6.2.1 Population Level Effects and Natural Gene Drives 
A gene drive is simply a way to “drive” or spread a gene through a population of wild animals at a 
rate greater than Mendelian inheritance would allow (Super-Mendelian inheritance).59 This can 
occur even if the gene imparts a neutral or negative fitness cost for the animal.59 As shown in Figure 
7, a mouse initially heterozygous for a typical gene will only transmit that gene to 50% of progeny.60 
In contrast, a gene drive can force the inheritance of that initially heterozygous gene in up to 100% 








































































Figure 8. A zygotic-homing gene drive mouse (red box, top left), two homologous chromosomes are shown each with the 
Cas9 gene (green), a gRNA expression element (red), and a cargo element (yellow) making up the gene drive cassette. The 
zygote formed from a mating between a gene drive mouse and a WT mouse is shown and the subsequent actions and 
outcomes of the gene drive activity. Image created with BioRender.8 
However, an alternative outcome to homing is the generation of an indel on the WT target 
chromosome via the error-prone repair pathways discussed in section 6.1.7 (e.g. NHEJ).30, 59 This 
results in the generation of a mouse with only one copy of the gene drive cassette. This can be 
especially detrimental in a gene drive situation as any indels present in this new allele will likely no 
longer have a complete gRNA binding site and are thus resistant to future cutting by the same 




because if a gene drive’s purpose is actually to knock out the gene at the target site, then an indel 
may still accomplish this. 
6.2.2.2 Germline-homing Gene Drive 
Genetically, a germline-homing gene drive differs from a zygotic-homing gene drive only in the 
promoters used to express the CRISPR nuclease and/or the gRNA, although in practice, modifying 
only the Cas9 promoter is simpler and no published experimental gene drives have done otherwise. 
The functional outcomes of an example germline-homing gene drive using Cas9 in mice are shown in 
Figure 9. 
 
Figure 9. A germline-homing gene drive mouse (red box, top middle), two chromosomes are shown for the somatic tissue, 
one is WT and the other contains the Cas9 gene (green), a gRNA expression element (red), and a cargo element (yellow) 
making up the gene drive cassette. No gene drive activity occurs in the somatic tissue. The germline tissue (grey box) is 
shown and the subsequent actions and outcomes of the gene drive activity in that tissue. If homing occurs, when mated to a 
WT mouse (blue box) the gene drive mouse is recapitulated in the offspring (red box, middle right). Image created with 
BioRender.8 
In this case, the gene drive mouse’s somatic tissue remains hemizygous for the gene drive because 
the gene drive is only active in the germline. In early embryogenesis in that tissue, before any 
gametes are produced, the Cas9 and gRNA are first expressed, coming together to form the RNP 
complex. The RNP then binds to the target site on the WT chromosome and cuts it. Just as described 
above in zygotic-homing, HDR then facilitates copying of the gene drive cassette to the WT 
chromosome due to the homology between the two chromosomes around the gene drive and the 
cut site.27, 59 Assuming successful homing, subsequent gametogenesis then leads to all gametes 
containing a copy of the gene drive cassette.27, 59 Again there is the alternative error-prone pathways 
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which can result in indel formation instead, if this were to occur all of the time, only half of the 
resulting gametes would have the gene drive cassette whilst the other half would have an indel on 
the WT chromosome.30, 59 In the case of a perfectly efficient gene drive, subsequent crossing of this 
mouse to a WT mouse means all offspring from this mating will be somatically hemizygous for the 
gene drive cassette, exactly recapitulating the original hemizygous parent.59 
6.3 GENE DRIVE APPLICATIONS 
6.3.1 Spreading Transgenes vs. Knocking Out Endogenous Genes 
At the molecular level, there are two key types of gene drive. As discussed above, one type carries 
along with it a cargo gene that will have some sort of effect on the population of wild organisms.59 
This can include beneficial genes that might do such things as confer resistance to particular diseases 
or it can include genes which negatively impact the target species such as removing resistance to 
pesticides, which will positively benefit agricultural industries or the environment.59 
The other type of gene drive contains no cargo and is instead placed in a location in order to disrupt 
a gene of interest.59 If the target site is chosen carefully, this can help reduce any deleterious effects 
seen by an indel instead of homing because the indel may disrupt the gene just as copying of the 
gene drive into that location does. A gRNA targeting an early coding region in the protein often leads 
to a frameshift mutation, knocking out the gene.70 Statistically speaking however, if an indel is an 
insertion or deletion that is a multiple of 3, no frameshifting will occur and potentially the gene 
won’t be knocked out.70 Some strategies to help increase the odds of generating a knockout are 
choosing an important location in a gene such as an active site of an enzyme or a splice donor site71, 
or use of multiple gRNAs that cut multiple important sites, or multiple sites close together to cause a 
large deletion between the two sites.21 To allow homozygous lethal or otherwise deleterious gene 
disruptions it is necessary to use a germline homing strategy which restricts the gene disruption to 
the germline tissue. The drive can thus spread through a population with minimal ill effects until it 
saturates the population and gene drive animals breed with one another. It is only then that any 
new offspring are homozygous for the gene disruption in somatic tissue. One caveat for this kind of 
drive is that the gene targeted for disruption must not be required in the germline or the animals 
won’t be fertile and thus won’t pass on the gene. 
6.3.2 Pest Control 
Invasive species incur a huge monetary cost on society, including the damage they do to the 
environment, agriculture and the cost of controlling or removing them, all adding up to an estimated 
$120 billion USD per year.72 The economic burden to the agriculture industry is also enormous, 
costing tens of millions of dollars to individual countries each year 73. In Australia alone, it costs an 
estimated $1 billion per year through agricultural and environmental damage.74 
Invasive rodents, including mice, pose a significant threat to biodiversity, particularly on islands and 
are the likely cause of hundreds of species extinctions.75-78 Previous attempts at invasive vertebrate 
pest control have had some success most commonly using the methods of poisoning, trapping, and 
hunting.79 Despite this, there are still many challenges including cost and ethical considerations.79 
Non-selective toxins are often used which can result in detrimental effects to non-target, native 
species.79 Concerns over the undue suffering of the pest species is also an issue with regards to how 
they are killed, how long it takes, and what pain they are put through.79 The cost of failed eradication 
attempts is especially important, as the reduction in pest species may only be temporary and lead to 







































100% of the time or 50% of the time depending on whether it is homozygous or hemizygous 
(respectively) for the gene drive allele. In a cross between a WT animal and an animal initially 
hemizygous for a germline-homing gene drive, efficiency as a percentage is calculated as shown 
below, where 𝑛 is the total number of offspring and 𝑥 is the number of offspring carrying the gene 
drive. 2(𝑥 − 0.5𝑛)𝑛 × 100% 
In recent years, a small number of studies have been published that experimentally tested gene 
drives. Below I summarise several key publications that advanced the field by implementing and 
investigating various features and types of gene drives. 
6.4.1 “The mutagenic chain reaction: A method for converting heterozygous to homozygous 
mutations” 
After initially being proposed by Esvelt et al. (2014), the first experimental CRISPR gene drive was 
published by Gantz and Bier (2015). A gene drive cassette was inserted into the D. melanogaster 
genome containing Cas9 driven by a germline promoter (Vasa) and a gRNA driven by a ubiquitously 
expressed promoter (U6) targeting the same locus on the homologous WT chromosome. 
As initially calculated in this paper, when female D. melanogaster were crossed to WT, out of 6 
females and 436 offspring, there was an allele conversion efficiency of 94.6-100%. Similarly, in the 2 
males and 91 offspring resulting from a cross to WT, there was a conversion efficiency of 96.2-100% 
There was also an overall 4% rate of mosaicism seen in the offspring and several cases where indels 
were created instead of homing events. It should be noted however, that these results were later 
called into question as a misinterpretation of the data, this is discussed further in section 6.4.5 
below where a follow-up paper analysed a similar gene drive system. 
Notwithstanding the controversy over the conversion rate, this was a very impressive result, 
especially as the first experimental CRISPR gene drive to be constructed. The efficiencies were 
incredibly promising and caused a widespread interest in generating more gene drives in various 
species. It also increased discussion on concerns over the safety of both gene drives and simply 
working on gene drives from an experimental standpoint. 
6.4.2 “Highly efficient Cas9-mediated gene drive for population modification of the malaria vector 
mosquito Anopheles stephensi” 
The Gantz and Bier paper was quickly followed up by another paper, this time in An. stephensi by 
Gantz et al. (2015). This paper took a more applied approach to the problem in its attempt to use 
cargo genes in a gene drive that have been shown to confer resistance to the malaria parasite 
Plasmodium falciparum.84 Apart from the addition of the cargo element, the gene drive was 
constructed in the same way as Gantz and Bier (2015) with Vasa-Cas9 and U6-gRNA elements, 
although the gene drive was now located on another chromosome with a corresponding change to 
the gRNA guide to target the new location in the homologous WT chromosome. 
Much larger numbers of animals were crossed in this paper; 3894 offspring were screened and a 
very impressive gene drive efficiency of 98.8% was observed. However, a critical issue was identified 
in the form of maternal carryover of Cas9 mRNA and gRNA. They found that in nearly every case 
(1781 of 1784 mosquitoes) where a female gene drive mosquito was a parent to the above progeny, 
the WT gene drive locus had been mutagenised by error-prone repair pathways. Contrasting this 
they found none of the progeny with a male gene drive parent showed this genotype. This is 

















































to the gene drive at a population level, essentially immunising that population from any further 
modification by the gene drive.81, 91 
In order to investigate these issues, both Vasa and nanos promoter-driven gene drives in D. 
melanogaster were created, the latter promoter also being germline-active, but with a lower 
expression level and reduced leaky somatic expression compared to Vasa.92 The nanos drive 
produced a 62% homing rate, 35% rate of resistance allele formation, and 1% were left with an 
intact WT allele. The Vasa drive generated a lower homing rate of 52% and a higher resistance allele 
formation rate of 48%. Their study design allowed them to determine when these resistance alleles 
were forming, and they showed that they could happen in the germline before fertilisation all the 
way through to post-zygotic embryos where maternally deposited Cas9 was still present. 
These drives were also tested across multiple lines of D. melanogaster where homing efficiency 
greatly varied. Among 7 different lines the nanos gene drive for instance had efficiencies between 
40-62%. These data suggest that genetic background may be an important determinant of gene 
drive activity. 
This paper also called in to question the original results from Gantz and Bier (2015) considering they 
both used the same promoter, at the same site, and in the same animal but got vastly different 
homing efficiencies. Their interpretation was a significant number of post-fertilisation indels were 
formed that disrupted the target site in a similar manner to the gene drive, but as those flies were 
only phenotyped and not genotyped by sequencing, the homing rate could not be accurately 
determined. 
6.4.6 “A CRISPR–Cas9 gene drive targeting doublesex causes complete population suppression in 
caged Anopheles gambiae mosquitoes” 
An An. gambiae gene drive paper by Kyrou et al. (2018) provided key experimental data as a 
demonstration of a suppression gene drive in a context which much more closely resembles how a 
functional gene drive release would occur. 
The gene drive was positioned to block formation of the female splice variant of the doublesex (dsx) 
gene. When homozygous in females, they produced an infertile, intersex animal. When homozygous 
in males or hemizygous in either sex, the animals developed normally and were fertile. The intended 
outcome would be gene drive spread until the entire population is composed of only males and 
infertile, intersex females. 
Real world conditions were emulated by use of a cage trial where mosquitoes could breed and 
interact freely with one another. Populations were started with a gene drive allele frequency of 
12.5% (150 gene drives males, 150 WT males, and 300 WT females). Each generation, 650 randomly 
selected eggs were used to seed subsequent generations and all hatched larvae were phenotyped 
for presence of the gene drive allele. 
The gene drive allele reached 100% frequency by generations 7 and 11 in two replicate cage trials, 
with no eggs produced in the subsequent generation. To investigate the effect that resistance alleles 
had, generations 2-5 were genotyped for indels at the gRNA target site. Up to 1.16% of non-gene 
drive alleles were found to contain indels but none were found to encode functional female dsx 
transcript. 
By performing a cage trial, which had yet to be done before this paper, Kyrou et al. (2018) showed 
very strong evidence for the efficacy of a field release of a gene drive. This was also an excellent 

















































replicate cage trials starting at 2.5% and 25% gene drive allele frequencies were all successful at 
eliminating the population (within 9 or 13 generations and 5 or 6 generations respectively). 
6.5 GENE DRIVE SAFETY 
Because of the enormous potential of CRISPR gene drives to rapidly alter wild populations, 
consideration of the potential ecological and environmental risks they pose has been intensive. 
There have been numerous papers discussing many different aspects of their safety, including safety 
during the experimental phase and safety concerns regarding potential release of gene drives into 
the wild. Nearly all experimental gene drive papers discussed above also address the safety issues 
and it was first brought up and discussed extensively in the original paper proposing CRISPR gene 
drives by Esvelt et al. (2014). 
6.5.1 Experimental Safety 
Safety when conducting experiments was of prime concern during the work in this thesis. Strategies 
were employed to confine the experimental gene drives so that they either cannot escape the 
laboratory, or if they do, their spread and effect on wild populations would be as minimal as 
possible. There are a number of key confinement strategies that have been laid out and are 
generally agreed upon in multiple different papers, initially outlined by Akbari et al. (2015). These 
include molecular, ecological, reproductive, and barrier confinement strategies.86 
The two key molecular strategies are a “split drive” and a synthetic target.86 These are both 
demonstrated in Figure 11. A split drive functions by separating the Cas9 nuclease and the gRNA on 
to separate chromosomes and allowing only one of these elements to be the homing cassette. This 
means that if a split drive were ever to be accidentally released into the wild, the Cas9 and gRNA can 
segregate away from each other as shown in Figure 12. This severely limits any continued homing 
except when the Cas9 and gRNA are inherited together by chance. 
 
Figure 11. Gene drive experimental safety. Left shows an ideal, functional gene drive that would be a likely design in a 
released drive. The Cas9 gene and gRNA are situated next to each other and they will target the homologous locus in a WT 
chromosome. Right shows a safer alternative which is more suited for experimentally testing in a lab. The mock “WT” 
chromosome contains a synthetic gRNA target not present in WT chromosomes. The Cas9 gene and the gRNA are also not 






Figure 12. Inheritance of a split drive system. Pattern of inheritance shown if a split gene drive with 100% homing efficiency 
were to be released into the wild. The gRNA gene drive is the homing construct that contains only a gRNA. The Cas9 is 
separated onto a different chromosome. Figured modified from Akbari et al. (2015). 
A synthetic target simply means that an extra animal model needs to be made with a synthetic 
sequence inserted into the chromosomal region that is homologous to the gene drive homing 
cassette. The gRNA in the homing cassette is designed to cleave this synthetic target sequence. Thus, 
the gene drive is incapable of cutting WT chromosomes, so if it were accidentally released into the 
wild, it could not function at all. The drawback to this system is the extra animal model that needs to 
be made and bred at relatively high numbers which then essentially functions as the experimental 
“WT” animal that the gene drive animal is crossed to. 
Ecological confinement strategies are basically directives to perform experiments outside of the 
habitable range of the wild organism so any escaped gene drive animals have no wild mates to breed 
with.86 This is of course, not always easy or even possible depending on what organism is being 
studied, especially given that pest species are often widespread. 
Reproductive confinement means that the laboratory strain is incapable of breeding with the wild 
strains.86 This is often not possible, but one example is using strains of D. melanogaster which have 
compound autosomes which can breed with one another but are incapable of producing offspring 
with wild D. melanogaster without those same compound autosomes.86 
The final, and likely most important confinement strategy is the physical barriers.86 This is simply the 
barriers and procedures that are in place to effectively prevent any gene drive animals from 
escaping into the wild. All the aforementioned confinement strategies are essentially in place as a 
backup in case the physical barrier strategies fail. Physical barriers include features such as the 
number of doors that are between the organisms and the outside world, whether the organisms 
should be handled when they are not anesthetised, and the use of low-temperature rooms or air-
blast fans to prevent any flying organisms from escaping. Physical containment strategies will differ 
considerably between different organisms, especially when considering small, flying insects in 




6.5.2 Release Safety 
Release safety has also been extensively discussed. This covers concepts such as trying to limit the 
spread of a gene drive and attempting to reverse or prevent changes induced by a gene drive. 
A “reversal drive”, as the name implies, is a secondary gene drive that attempts to reverse the 
changes induced by a previously released gene drive.59 It functions in the exact same way as a 
normal gene drive, except it is targeting the genomic locus of the previously released gene drive to 
change it back into essentially a WT animal.59 The only caveat being that the Cas9 and gRNA 
components can never be removed by the gene drive because they are still required to spread the 
reversal drive.59 As mentioned in section 6.4.3, a reversal drive has been constructed and exhibited 
similar homing rates as standard gene drives.85 
An “immunisation drive” is still a conceptual idea but is a potentially valid strategy that can be 
deployed in response to another gene drive that has been released (either deliberately or 
accidentally). An immunisation drive is again another form of gene drive, but it would function by 
targeting the same target site of another gene drive with the intention of changing that target 
sequence to prevent the other gene drive from spreading.59 
Trying to limit the spread of gene drives is a key concern among researchers, and there are no easy 
solutions for when a successful gene drive is released. It is likely to spread rapidly, crossing national 
borders, and potentially affecting very closely related species or different sub-populations that are 
unintended targets. A couple of different solutions do present themselves though - in certain 
circumstances a sub-population may be entirely isolated from others by means of being 
geographically isolated on an island, indeed invasive rodents on islands are an excellent target for an 
eradication drive.59 A genetic solution to this problem is also apparent in the form of polymorphisms 
that are fixed in the target population so long as the same polymorphism is not fixed in non-target 
populations.59 However, this requires a great deal of sequencing data about the genomes of the 
different populations.59 
6.6 CRISPR GENE DRIVE MODELLING 
Experimentally, in small populations of tightly controlled insects, gene drives are looking promising. 
This is not necessarily going to translate well into large populations where many new and 
challenging variables can come into play. To this end, it is essential to employ computational 
modelling of these systems to get some idea of how they will behave. 
Many factors influence how a model is constructed and simulated. Primary considerations include 
the specific species and how they mate and breed. Depending on the model, many other aspects can 
be taken into consideration for the simulation too, such as social behaviour, how spread out the 
mice are, how likely they are to mingle with one another, etc. Often modeling is panmitic such that 
mate selection is random and does not depend on the animals’ likelihood to be near one another, 
whereas spatial modelling can account for this but is more computationally intensive. For modelling 
gene drives, some key pieces of data specific to them are the rate of homing, rate of resistance allele 
generation, and rate of DNA cleavage. It’s also important to consider the type of gene drive - 
different types of suppression drives will affect the population in different manners to one another 
and to a simple gene drive carrying a neutral cargo gene. 
A key outcome from the modelling has shown that a CRISPR gene drive will indeed spread rapidly 




resistance allele formation will severely limit their spread.91, 110, 111 Even naturally occurring 
resistance alleles might already be present in wild populations due to natural genetic variation.91, 110 
When considering the spread of a cargo element as opposed to any sort of gene knockdown or 
population suppression gene drive, it has become clear that unless the error-prone repair pathways 
are suppressed, then resistance to the drive will inevitably evolve.90 
When looking at modelling CRISPR gene drives in vertebrate pests for population suppression on 
islands, Prowse et al. (2017) published a paper where we showed that simple gene drives containing 
only a single gRNA were incapable of eradicating the population. More complex modelling was done 
however, whereby multiple gRNAs are present in a gene drive that target separate, but nearby 
locations as a potential method to remove resistance alleles due to subsequent cleavage events 
giving the gene another chance to “overwrite” the resistance allele with the gene drive.81 Depending 
on the type of gene drive, we showed that multiple gRNAs effectively eradicated the island 
populations of invasive vertebrates.81 
A simpler approach to modelling this in Marshall et al. (2017) and Noble et al. (2017) showed that 
multiple gRNAs were sufficient to overcome the problem of resistance. This does not adequately 
account for the molecular mechanisms that are likely to take place with multiple gRNAs however, as 
multiple nearby cut sites generally result in a large deletion between the two sites which would be a 
single resistance allele in this case that cannot be recovered from by the gene drive. In Prowse et al. 
(2017), we modelled with the assumption that the multiple gRNAs were expressed at different time 
periods however, preventing the occurrence of large deletions. It should be noted, that if the 
purpose of the gene drive is to knock out a gene, as discussed in section 6.3.1 and demonstrated in 
the mosquito cage trials,93 a deletion of a critical gene may also be beneficial to the drive and 




The broad aim of this thesis was to research and develop advances in CRISPR technology. This can be 
broken down into a major and minor aim. 
The major aim was to design, implement, and test CRISPR-based gene drives in M. musculus. This 
was done separately with Cas9 and Cas12a nucleases. Both versions of these were also implemented 
as zygotic and germline-homing gene drives controlled using appropriate promoters for the 
nucleases. After validation of the individual components of the gene drives, specific outcomes to be 
measured for each gene drive were the homing efficiency, number of resistance alleles generated, 
and number of uncut WT alleles. All gene drive research was to be carried out with the key safety 
features of a split drive system and a synthetic target as discussed in section 6.5.1. 
The minor aim was to develop a suite of CRISPR plasmids allowing for the streamlining and 








8 CAS9 DUAL GRNA PAPER 
8.1 INTRODUCTION 
As discussed in section 6.1.5, one of the commonly used CRISPR genome editing tools is an all-in-one 
plasmid that contains both a CRISPR nuclease and the associated gRNA under appropriate promoters 
that allow the expression of the nuclease and gRNA. This greatly simplifies the use of CRISPR as the 
plasmid can be introduced into cultured cells, tissue, or zygotes to induce editing without a 
requirement to generate Cas9 protein or gRNA beforehand. 
What was not previously mentioned is that often it is beneficial to simultaneously induce two cuts, 
using two different gRNAs. This can be used to create large deletions between the two sites, to 
knockout multiple genes simultaneously, to induce chromosomal translocations, to insert multiple 
sequences into the genome at once, or, in the case of Cas9 Nickase it can be used to induce two 
nearby nicks to induce a single DSB whilst greatly reducing off-target cutting.113, 114 
Previous methods to accomplish double-gRNA activity either involved the use of multiple plasmids 
or had polymerase chain reaction (PCR)-dependent or complicated and time-consuming cloning 
strategies to create the required plasmid expressing multiple gRNAs.115-118 As such, the publication 
included in this thesis chapter provides a significant advance in CRISPR tool development, and 
describes a suite of plasmids that allow a PCR-free, one-step generation of Cas9/Nickase genome 
editing plasmids containing two distinct gRNAs. 
8.2 “VERSATILE SINGLE-STEP-ASSEMBLY CRISPR/CAS9 VECTORS FOR DUAL GRNA EXPRESSION” 
PAPER 
The 11 pages following the statement of authorship below contain the full, published paper. The 
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Abstract
CRISPR/Cas9 technology enables efficient, rapid and cost-effective targeted genomic mod-
ification in a wide variety of cellular contexts including cultured cells. Some applications
such as generation of double knock-outs, large deletions and paired-nickase cleavage
require simultaneous expression of two gRNAs. Although single plasmids that enable multi-
plex expression of gRNAs have been developed, these require multiple rounds of cloning
and/or PCR for generation of the desired construct. Here, we describe a series of vectors
that enable generation of customized dual-gRNA expression constructs via an easy one-
step golden gate cloning reaction using two annealed oligonucleotide inserts with different
overhangs. Through nucleofection of mouse embryonic stem cells, we demonstrate highly
efficient cleavage of the target loci using the dual-guide plasmids, which are available as
Cas9-nuclease or Cas9-nickase expression constructs, with or without selection markers.
These vectors are a valuable addition to the CRISPR/Cas9 toolbox and will be made avail-
able to all interested researchers via the Addgene plasmid repository.
Introduction
CRISPR/Cas9 technology is a powerful genome editing tool that has become widely used by
researchers to generate targeted genetic modifications in many contexts including cultured
cell lines and zygotes. CRISPR/Cas9 offers several advantages over preexisting genome editing
technologies including ease of use, relatively low cost and high activity [1–5]. The CRIPSR/
Cas9 platform comprises two components; Cas9, which functions as a programmable endonu-
clease that generates a blunt-ended double-stranded break (DSB) and a ~100 nt guide RNA
(gRNA), in which the ~20 nt at the 5’ end directs Cas9 to the target site via RNA:DNA comple-
mentary base pairing [6–8]. Generation of a targeted DSB can be achieved by delivery of Cas9
and gRNA components in plasmid, RNA or ribonucleoprotein (RNP) forms. For some ap-
plications, such as cultured cells, plasmids are generally preferred due to their ease of genera-
tion and stability. Commonly used plasmids for expression of Cas9 or Cas9-nickase (D10A)
and single gRNA are available from the Zhang laboratory and can be obtained through the
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Addgene plasmid repository. These plasmids contain both gRNA and Cas9 expression cas-
settes in a single plasmid with optional selection markers such as puromycin or GFP to facili-
tate screening. Importantly, generation of a unique customized gRNA of interest can be
performed easily as the gRNA cloning site contains BbsI restriction sites, allowing a one-step
golden gate cloning approach for insertion of a pair of annealed oligonucleotides containing
the specific ~20 bp guide sequence [6, 9].
To simultaneously target a pair of genomic regions, expression of two gRNAs is required.
While this can be achieved by co-transfection of two plasmids, this process can be inefficient.
To achieve efficient dual cuts, all CRISPR/Cas9 components with dual-gRNAs should be
expressed from a single plasmid. Single plasmids expressing multiple gRNAs have been devel-
oped, however generation of the desired constructs using those available plasmids require mul-
tiple cloning and/or PCR steps. Here we modify commonly-used vectors from the Zhang
laboratory so that each plasmid can express two gRNAs and can be generated via a simple one-
step cloning method. We show that these plasmids, termed dual-gRNA plasmids, provide an
efficient tool for experiments requiring simultaneous expression of two gRNAs such as multi-
plexed knock-out of two genes, generation of large deletions and generation of indels using
Cas9-nickase. These vectors are a valuable addition to the CRISPR/Cas toolbox and will be
made available through the Addgene plasmid repository.
Results
Generation of vectors
To generate plasmids that permit simultaneous expression of two gRNAs, we inserted an
additional hU6-gRNA expression cassette into the available CRISPR plasmids from the Zhang
laboratory. The second cassette was positioned in the opposite orientation to the original
hU6-gRNA expression cassette to reduce the possibility of recombination (Fig 1A). The addi-
tional cassette also contains a BbsI golden gate site at the guide insertion site as per the original
cassette. However, unlike the original BbsI site which generates GTTT and GGTG overhangs,
the new site generates CGGT and TTTA overhangs (Fig 1B) allowing simultaneous targeted
insertion of two annealed oligonucleotides with different complementary overhangs in a one-
step digestion-ligation reaction (Fig 1C; see below). We added the extra gRNA cassette to the
following Cas9 nuclease vectors: pX330 (no selection marker), pX458 (GFP selection marker)
and pX459.V2.0 (puromycin selection marker), and to the following Cas9-nickase vectors:
pX335 (no selection marker), pX461 (GFP selection marker) and pX462.V2.0 (puromycin
selection marker). Those vectors were named pDG330, pDG458, pDG459, pDG335, pDG461
and pDG462, respectively.
Efficient generation of custom dual-gRNA vector using a one-step
cloning protocol
Having generated the dual-gRNA vectors, we next tested whether we could simultaneously
insert two annealed oligonucleotide duplexes in a one-step cloning process. We designed two
gRNA oligonucleotide inserts targeting the mouse Sox1 and Sox3 genes. These inserts carried
BspMI and SacI restriction sites at the original and second hU6-gRNA sites, respectively.
Annealed oligonucleotide duplex pairs and pDG459 vector were subjected to a one-step diges-
tion-ligation cycling protocol followed by bacterial transformation (Fig 1C). All 12 colonies
analyzed contained vectors with correct assembly based on their RFLP pattern (Fig 1D). Simi-
lar results were obtained with other dual-gRNA plasmids (pDG330, pDG335, pDG461 and
pDG462) with correct assembly in 21/23 colonies based on RFLP, confirmed by sequencing in
Dual gRNACRISPR/Cas9 vectors
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Fig 1. Generation of dual-gRNA expressing vectors. (A) Schematic of dual-gRNA vectors. (B) Golden gate cloning
strategy for insertion of specific guide sequences into each cassette. Note that the BbsI sites generate different
overhangs after restriction digest. Red highlights indicate the BbsI sites, yellow and green highlights are part of hU6
promoter and gRNA, respectively, that are necessarily present in the plasmid. Blue and purple highlights indicate the
unique customized guide sequences (C) One-step cloning protocol for the generation of customized dual-gRNA
vectors. (D) Insertion of Sox1A and Sox3A oligonucleotide duplexes into pDG459 resulted in correct insertions in all 12
Dual gRNACRISPR/Cas9 vectors
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9 samples (data not shown). This demonstrates that our dual-gRNA vector design combined
with the one-step cloning protocol can allow easy and efficient generation of CRISPR/Cas9
vectors with dual-gRNA expression cassettes.
Efficient generation of DSB at two sites using vectors expressing Cas9
nuclease and dual-gRNAs
We next tested whether the dual-gRNA Cas9-nuclease vectors could efficiently induce indels
or deletions through simultaneous digestion at two target sites. Four different pDG459 deriva-
tives were initially generated; the first targeted Sox1 site A and Sox3 site A (pDG459 Sox1A/
Sox3A), the second targeted Sox1 site B and Sox3 site B (pDG459 Sox1B/Sox3B), the third tar-
geted Sox1 site A and Sox1 site B (pDG459 Sox1A/Sox1B) which are separated by 51 bp and
the last targeted Sox3 site A and Sox3 site B (pDG459 Sox3A/Sox3B) which are separated by 47
bp (Fig 2A). All target sequences contained restriction sites and hence indel generation at each
site could be assayed by RFLP analyses. In addition, efficient digestion by pDG459 Sox1A/
Sox1B or pDG459 Sox3A/Sox3B gRNAs should cause a deletion of ~50 bp which can be read-
ily detected by PCR. Each of the four constructs were separately transfected to the mouse ES
cells followed by puromycin selection to ensure only transfectants were harvested. Sox1 and
Sox3 PCRs were performed on Sox1A/Sox3A-treated samples followed by a BfuAI (isoschizo-
mer of BspMI) and SacI RFLP assay to assess indel generation at Sox1A and Sox3A sites,
respectively. Both RFLP analyses indicated that pDG459 Sox1A/Sox3A plasmid induced muta-
tions with ~100% efficiency at both Sox1A and Sox3A sites (Fig 2B and S1 Fig). Highly efficient
mutagenesis of the Sox1B and Sox3B sites was also detected by ApaI and SfoI RFLP assays in
pDG459 Sox1B/Sox3B-trasfected cells (Fig 2B and S1 Fig). We next examined whether dele-
tion of the sequences between the cut sites could be induced by pDG459 Sox1A/Sox1B or
Sox3A/Sox3B transfection. PCR products corresponding to deletion alleles were readily gener-
ated in pDG459 Sox1A/Sox1B- or Sox3A/Sox3B-treated samples but not in the WT and the
unpaired controls upon Sox1 or Sox3 PCR (Fig 2B, S1 Fig). Efficient dual nuclease activity was
also demonstrated using pDG330- and pDG458-derived constructs (S2 Fig). Together, these
data indicate that all-in-one dual-gRNA Cas9 nuclease vectors can facilitate efficient simulta-
neous cutting at two gRNA target sites.
Efficient DSBs induced by plasmids expressing Cas9-nickase and dual
paired-gRNAs
Expression of Cas9-nickase with a single gRNA results in a ssDNA break that is typically
repaired without causing a mutation. In contrast, expression of Cas9-nickase and two gRNAs
targeting closely spaced sites on opposite DNA strands will generate a staggered DSB, repair
of which results in indel mutations [10, 11]. We next tested the dual-gRNA Cas9-nickase vec-
tors to assess whether they could efficiently induce DSBs via expression of gRNA pairs. We
generated pDG462 derivatives targeting Sox1A/Sox1B and Sox3A/Sox3B which have the req-
uisite orientation and spacing to permit mutagenesis by paired-nickase activity (Fig 2A). As
negative controls, we also generated pDG462 targeting Sox1A/Sox3A and Sox1B/Sox3B which
are not paired therefore should not generate indel mutations. Vectors were transfected to
mouse ES cells followed by puromycin selection. T7E1 heteroduplex assays revealed that
pDG462 Sox1A/Sox1B and Sox3A/Sox3B efficiently generated mutations at Sox1 and Sox3,
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Fig 2. Efficient dual cuttingmediated by pDG459 vector. (A) Schematic of gRNA target sites in the Sox1 and Sox3
genes. (B) Highly efficient dual cuts induced by vectors derived from pDG459 as indicated by PCR and RFLP analyses. WT
products were cut by restriction enzymes resulting in bands indicated by the red arrows. Absence of these bands in dual-
gRNA vector-treated samples indicated that the Cas9 nuclease and the gRNAs efficiently induced mutations thus
destroying the restrictions sites. Efficient cuts from pDG459 Sox1A/Sox1B and pDG459 Sox3A/Sox3B were indicated by
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respectively (Fig 3 and S3 Fig). In contrast, there was no evidence of mutations after transfec-
tion of the non-paired control plasmids (Fig 3 and S3 Fig). Efficient mutation of Sox3was also
achieved using dual-gRNA nickase vectors pDG335 and pDG461 expressing Sox3A/Sox3B (S4
Fig). Together, these data demonstrate efficient targeted mutagenesis using dual-gRNA
paired-nickase vectors.
Discussion
Plasmids from the Zhang laboratory have greatly simplified generation of customized gRNA-
Cas9/Cas9-nickase expression constructs through utilization of the golden gate cloning strat-
egy. Users only need to anneal a pair of oligonucleotides and ligate them into the vectors via a
one-step cloning process, circumventing multiple rounds of PCR and cloning [6, 9]. We modi-
fied available plasmids to allow simultaneous insertion of two oligonucleotide duplex inserts
using the simple one-step cloning method. These modified vectors provide a user-friendly and
cost-effective system to perform experiments that require simultaneous expression of two
gRNAs. Additionally, we have shown that both gRNA cassettes are active and induce muta-
tions with high efficiency at both target sites when combined with reliable transfection and
selection methods.
Other recent studies have also generated CRISPR/Cas9 vectors that are able to express dual-
gRNAs simultaneously, most of which also take advantage of golden gate cloning. However,
unlike the dual-gRNA vectors described herein, these require multiple rounds of cloning and/
or PCR [12–15]. Additionally, the strategy to express dual-gRNA as a polycistronic transcript
that is split by Csy4 RNA polymerase [16] has been shown to have low efficiency [17]. Further-
more, our dual-gRNA vectors are available with Cas9 nuclease or nickase, and with or without
selection markers, and can therefore be utilized in a broad range of experimental contexts.
Fig 3. Paired-nickase DSB induction by pDG462. Sox1 or Sox3 PCR followed by T7E1 assay was
performed on pDG462-transfected samples. Mutations in Sox1 and Sox3were induced by pDG462 Sox1A/
Sox1B or pDG462 Sox3A/Sox3B, respectively, as indicated by the digested products after T7E1 treatment
(blue arrows). Mutations were not induced by non-paired-nickase control plasmids (pDG462 Sox1A/Sox3A or
pDG462 Sox1B/Sox3B). Complete figures with more independent samples can be found in S3 Fig.
https://doi.org/10.1371/journal.pone.0187236.g003
Dual gRNACRISPR/Cas9 vectors
PLOSONE | https://doi.org/10.1371/journal.pone.0187236 December 6, 2017 6 / 11
44
Vectors from other studies, although more complicated, are useful when conducting experi-
ments requiring more than 2 gRNAs since those vectors can bear up to 7 gRNAs in a single
vector [13, 14].
Our one-step cloning strategy could be applied to generate multiple gRNAs by adding
more hU6-gRNA cassettes. To do so, the BbsI sites of the new cassettes would need to be mod-
ified to produce different unique overhangs upon digestion. This cloning approach could also
be combined with other commonly used CRISPR platform variants such as Cpf1, dCas9-Fok1,
Cas9-HF, eSpCas9, and other Cas9 orthologs or mutants that recognize different PAM
sequences.
Off-target mutagenesis is one of the most significant issues of CRISPR/Cas9 genome editing
[18, 19], particularly for therapeutic applications. The paired-nickase strategy has previously
been shown to minimize the off-target effects that are a feature of Cas9 nuclease [20, 21]. We
therefore anticipate that the dual-gRNA nickase vectors will be an attractive option for users
who require efficient mutagenesis and with maximum specificity.
Efficient dual nuclease cuts are useful for generating targeted large deletions for many pur-
poses such as studying the function of enhancers or long non-coding RNA. In some situations,
targeted large deletions are required to delete an exon such as for DMD therapeutics via exon
skipping [22–24] or to delete a centromere for chromosome removal [25]. Dual-gRNA Cas9
vectors could also be used for simultaneous KO of two different genes. We also offer our dual-
gRNA nuclease vectors for efficient generation of chromosome translocations to model dis-
eases such as Burkitt’s lymphoma or acute myeloid leukemia [12]. Dual DSBs may also aid
insertion of flanking loxP sequences for conditional deletion and for insertion of gene swap
constructs [26, 27]. Furthermore, these vectors can also be used for injection into mouse
zygotes for the generation of mutant mice [28]. Taken together our vectors are a valuable
addition to the CRISPR/Cas9 toolbox and should be useful for many CRISPR/Cas9-based
applications.
Materials andmethods
Plasmid and gRNA design
Plasmids pX330, pX335, pX458, pX459.V2.0, pX461 and pX462.V2.0 were gifts from Feng
Zhang (Addgene plasmid 42230, 42335, 48138, 62988, 48140 and 62987, respectively) [6, 9].
The Cas9 or Cas9-nickase of those plasmids are derived from Streptococcus pyogenes Cas9
which recognizes NGG PAM sequences. The BbsI sequences from pX330 were replaced with
the second version of BbsI sequences (see Fig 1B). The hU6-gRNA region was then amplified
using primers containing NotI sites. PCR products were then ligated to original plasmids at
the NotI site. Guide sequences targeting Sox1A, Sox1B, Sox3A and Sox3B were
, ,
and , respectively, which were designed
using online CRISPR design tool http://crispr.mit.edu/. The modified plasmids have been sub-
mitted to Addgene with plasmid reference number #100898–100993.
One step cloning for the generation of customized dual-gRNA plasmid
Forward and reverse oligonucleotides containing the guide sequences for Sox1A, Sox1B,
Sox3A and Sox3B with appropriate overhangs (Table 1) were phosphorylated and annealed by
mixing 100 pmol of each pair and 0.5 μL T4 PNK (NEB) then incubated at 37˚C for 30 min-
utes, 95˚C for 5 minutes and slowly ramped to RT. Annealed oligonucleotides were diluted
1 in 125. Pairs of oligonucleotide duplexes were ligated into the empty vectors in a one-step
digestion ligation reaction by mixing the diluted duplex oligonucleotide pairs (1 μL each) with
Dual gRNACRISPR/Cas9 vectors
PLOSONE | https://doi.org/10.1371/journal.pone.0187236 December 6, 2017 7 / 11
45
100 ng empty vector, 100 μmol of DTT, 10 μmol of ATP, 1 μL of BbsI (NEB), 0.5 μL of T4
ligase (NEB) and NEB-2 buffer in 20 μL of reaction. The mixture was placed in a thermocycler
and cycled 6 times at 37˚C for 5 minutes and 16˚C for 5 minutes before bacterial transforma-
tion. Plasmids were prepared using miniprep kit (Qiagen) or PureLink1HiPure Plasmid
Midiprep Kit (Life Technologies). Correct insertion of oligonucleotide duplexes into the vec-
tors was confirmed by Sanger sequencing using the following primers:
(first insert) and (second insert). It is recom-
mended to digest the vectors using BbsI before sequencing as correct insertion should remove
the BbsI sites.
Cell culture and transfection
R1 mouse embryonic stem cells from Andras Nagy’s laboratory (Established from a male blas-
tocyst hybrid of two 129 substrains (129X1/SvJ and 129S1/SV-+p+Tyr-c Kitl Sl-J/+)) were used
for all experiments. Cells were cultured in 15% FCS/DMEM supplemented with LIF, 3 μM
CHIR99021 (Sigma), 1 μMPD0325901 (Sigma), 2 mMGlutamax (Gibco), 100 μMnon-essen-
tial amino acids (Gibco) and 100 μM 2-mercaptoethanol (Sigma). One million ES cells were
nucleofected with 3 μg of plasmid DNA using the Neon™ Transfection System 100 μL Kit (Life
technologies) at 1400 V, 10 ms and 3 pulses according to the manufacturer’s protocol. For
transfection of pDG459 and pDG462, puromycin selection (2 μg/mL was initiated 24 hours
post transfection for 48 hours. GFP FACS was performed on cells transfected with pDG458
and pDG461 48 hours post transfection. Surviving cells were cultured for 4–7 days without
selection before harvesting. Cells transfected with plasmid pDG330 and pDG335 did not
undergo any selection.
DNA extraction, PCR, RFLP and T7E1 assay
Genomic DNA was extracted from 1–2 million cells using High Pure PCR Template Prepara-
tion Kit (Roche) according to the manufacturer’s instructions. Sox1 PCR was performed using
primers F: and R: .
Sox3 PCR used primers F: and R:
. RFLP or T7E1 assay was performed by mixing 5 μL of PCR products (with-
out purification) with the restriction enzymes or T7E1 enzyme (NEB) in a total volume of
20 μL and incubated for 1 hour at the suggested optimal temperatures. Prior to T7E1 assay,
PCR products were slowly re-annealed to form heteroduplex products by heating the PCR
products at 95˚C for 5 minutes and slowly ramped down to room temperature.
Table 1. List of oligos used to generate the dual-gRNA targeting plasmids.





Grey highlights indicate the sequence of the guides
https://doi.org/10.1371/journal.pone.0187236.t001
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Supporting information
S1 Fig. Efficient dual cutting mediated by pDG459 vector. Extended figures of Fig 2B with
more independent samples. (A) BfuAI and SacI RFLP analyses indicated efficient dual cuts
from pDG459 Sox1A/Sox3A. (B) ApaI and SfoI RFLP analyses indicated efficient dual cuts
from pDG459 Sox1B/Sox3B. WT products after digestions (red arrows) were absent in
pDG459-treated samples. (C) Large deletions were induced in the Sox1 region in pDG459
Sox1A/Sox1B-treated samples. (D) Large deletions were induced in the Sox3 region in
pDG459 Sox3A/Sox3B-treated samples. Large deletion fragments are indicated with blue
arrows. Each sample came from independent transfection (n 3).
(TIF)
S2 Fig. Mutation inductions mediated by vectors pDG330 and pDG458. (A) Transfection of
pDG330 Sox1A/Sox3A into mouse ES cells induced mutations at both targets which were indi-
cated by smaller fragments after T7E1 assay (blue arrows). (B) BfuAI and SacI RFLP were used
to assess the mutation induction in Sox1A and Sox3A sites, respectively, after treatment of
pDG458 Sox1A/Sox3A followed by GFP FACS enrichment. Presence of WT products pro-
duced smaller bands after restriction digestions (red arrows) which were absent in pDG458
Sox1A/Sox3A-treated samples. Each sample came from independent transfection.
(TIF)
S3 Fig. Paired-nickase DSB induction by pDG462. Extended figures of Fig 3 with more inde-
pendent samples. Smaller bands produced after T7E1 digestion (blue arrows) indicated pres-
ence of mutation in samples treated with paired-nickase pDG462 Sox1A/Sox1B (A) or Sox3A/
Sox3B (B). Each sample came from independent transfections.
(TIF)
S4 Fig. Paired-nickase-mediated mutation inductions by pDG335 and pDG461 vectors.
T7E1 assay showed that expression of paired-nickase gRNAs Sox3A/Sox3B from pDG335 (A)
or pDG461 (B) induced mutations in the Sox3 locus as indicated by the presence of cut prod-
ucts (blue arrows). Each sample came from independent transfections.
(TIF)
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S1 Fig. Efficient dual cutting mediated by pDG459 vector. 
Extended figures of Fig 2B with more independent samples. (A) BfuAI and SacI RFLP analyses indicated efficient 
dual cuts from pDG459 Sox1A/Sox3A. (B) ApaI and SfoI RFLP analyses indicated efficient dual cuts from 
pDG459 Sox1B/Sox3B. WT products after digestions (red arrows) were absent in pDG459-treated samples. (C) 
Large deletions were induced in the Sox1 region in pDG459 Sox1A/Sox1B-treated samples. (D) Large deletions 
were induced in the Sox3 region in pDG459 Sox3A/Sox3B-treated samples. Large deletion fragments are 





S2 Fig. Mutation inductions mediated by vectors pDG330 and pDG458. 
(A) Transfection of pDG330 Sox1A/Sox3A into mouse ES cells induced mutations at both targets which were 
indicated by smaller fragments after T7E1 assay (blue arrows). (B) BfuAI and SacI RFLP were used to assess 
the mutation induction in Sox1A and Sox3A sites, respectively, after treatment of pDG458 Sox1A/Sox3A followed 
by GFP FACS enrichment. Presence of WT products produced smaller bands after restriction digestions (red 







S3 Fig. Paired-nickase DSB induction by pDG462. 
Extended figures of Fig 3 with more independent samples. Smaller bands produced after T7E1 digestion (blue 
arrows) indicated presence of mutation in samples treated with paired-nickase pDG462 Sox1A/Sox1B (A) or 





S4 Fig. Paired-nickase-mediated mutation inductions by pDG335 and pDG461 vectors. 
T7E1 assay showed that expression of paired-nickase gRNAs Sox3A/Sox3B from pDG335 (A) or pDG461 (B) 
induced mutations in the Sox3 locus as indicated by the presence of cut products (blue arrows). Each sample 








9 CAS9 ZYGOTIC AND GERMLINE GENE DRIVE PAPER 
9.1 INTRODUCTION 
This paper addresses the major aim of this thesis by the design, implementation, and testing of both 
zygotic and germline CRISPR/Cas9-based gene drives in M. musculus.  
As discussed in sections 6.2-6.4, CRISPR gene drive research, although offering enormous potential, 
is still in its infancy. When the research presented in this thesis started, there had only been 3 
published papers that contained experimental CRISPR gene drives.82, 83, 85 Since then, that number 
has increased to 21 papers with all experiments performed in flies and mosquitoes except for a 
single yeast paper.82, 83, 85, 89, 90, 93-107, 109 The idea to generate a CRISPR gene drive in a vertebrate, a 
radically different species to that reported in the other papers, presented a great opportunity for 
novel and important research. The “single-generation” homing demonstrated in mice by Grunwald 
et al. (2019) further bolstered the promise of vertebrate gene drives for invasive pests. 
The approach taken here was with safety as paramount, utilising both a split drive and a synthetic 
target to reduce the risk of an accidental release and spread of the gene drive to basically nil. The 
research outcomes, methods and rationale for experimental designs are fully discussed within the 
paper below. Further details regarding additional experiments and methods not relevant to the final 
publication are presented in section 9.3. 
9.2 “PROGRESS TOWARD ZYGOTIC AND GERMLINE GENE DRIVES IN MICE” PAPER 
The 10 pages following the statement of authorship below contain the full paper proof, currently 
accepted for publication in The CRISPR Journal. The following 15 pages after that contain the 

















Large Δ mosaic 0 2
Indel 17 0
Indel mosaic 39 0
No ac�vity/indel mosaic 27 6
No ac�vity 5 0
Totals




































1 1.01 1.06 0.93 0.9
0.98 0.96 0.89
















Supplemental Figure 1. Demonstration of Neo-gRNA cleavage activity at its target binding site. 
Mouse ES cells containing the target binding site for Neo-gRNA were transfected with a plasmid 
containing U6-driven Neo-gRNA and a plasmid (pX459) containing CMV-driven hSpCas9. RFLP 
analysis was performed around the cut site. Digestion of Neo-gRNA/T7 band demonstrates 
successful cutting by Neo-gRNA. 
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Supplemental Figure 2. Phenotyping TyrgRNA-Tomato mice. (A, B) Representative immunofluorescence 
images of ear notches of (A) TyrgRNA-Tomato mice and (B) WT mice, showing expression of dTomato. (C) 
A representative F2 litter of TyrgRNA-Tomato mice. Black mice were heterozygous for TyrgRNA-Tomato. White 
mice were homozygous for TyrgRNA-Tomato. 
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Supplemental Figure 3. TyrTarget homozygote phenotyping, showing black coats. 
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Supplemental Figure 4. TyrgRNA-Tomato copy number determination for zygotic-homing mice. 
Representative ddPCR showing copy number of TyrgRNA-Tomato (with 95% CI) in five Rosa26Cas9/+ ; 
TyrgRNA-Tomato/Target mice with dappled coats. 
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Supplemental Figure 5. Large deletion genotyping. (A) PCR showing large deletions around TyrTarget 
in four Rosa26Cas9/+ ; TyrgRNA-Tomato/Target mice with dappled coats. The black arrow shows expected 
band (∼4 kb) for no deletion/small indels. The red arrows show large deletions of varying size. (B) 
Sanger sequencing traces from three Rosa26Cas9/+ ; TyrgRNA-Tomato/Target mice with dappled coats 
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Supplemental Figure 6. Vasa-Cas9 expression. (A) RT-qPCR showing expression levels (with 95% CI) 
of the Vasa-Cas9 lines in various tissue types. (B) ddPCR copy number assay showing the genomic 
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Supplemental Figure 7. Extended germline-homing genotyping data. (A) Data shows number of 
TyrTarget alleles with an indel (TyrTargetΔ) as a percentage of total TyrTarget alleles with and without 
indels in the offspring of gene drive mice (as per Figure 3), broken down into Vasa-Cas9 line and sex. 
Exact percentage of indels is shown in each bar and total number of TyrTarget alleles is shown at the 
top of each column. (B) Representative TyrTarget cut site digestion with MwoI (as indicated) and T7 
Endonuclease (all samples), black arrows show expected uncut bands due to destruction of MwoI 
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Supplemental Figure 8. Phenotyping of Rosa26Cas9/+ ; TyrgRNA-Tomato/Target mice containing no indels. 
Representative immunofluorescence images of ear notches of aforementioned mice (A, C) and WT 
mice (B, D), showing expression of dTomato (A, B) and expression of EGFP (C, D). 
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Supplemental Figure 9. Breakdown of zygotic-homing indel formation based on parent of origin. 
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Supplemental Figure 10. Cas9 expression comparison. RT-qPCR showing expression levels (with 95% 
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Supplemental Tables 
Mouse ID Sex TyrgRNA-Tomato alleles Total TyrTarget alleles TyrTargetΔ alleles 
3.2b male 23 18 4 
27.1d male 16 17 3 
27.1e male 3 6 0 
33.2e male 2 5 0 
33.2f male 9 3 0 
33.2g male 11 6 1 
24.1a female 8 5 0 
33.2a female 19 14 0 
33.2b female 3 5 0 
35.1b female 3 1 1 
35.1d female 4 4 0 
35.1e female 3 3 0 
35.2a female 24 27 3 
35.2c female 0 8 4 
36.2d female 21 26 1 
37.2a female 8 6 1 
37.2b female 10 3 0 
37.2c female 12 19 0 
Supplemental Table 1. Germline-homing individual mouse genotyping data for Vasa-Cas9-2. 
Breakdown of the ratio of inherited alleles for the offspring of the listed Vasa-Cas9-2/+ ; 
TyrgRNA-Tomato/Target mice crossed to WT. Data collated to produce Vasa-Cas9-2 data in Figure 4 and 
Supplemental Figure 7. 
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Mouse ID Sex TyrgRNA-Lite alleles Total TyrTarget alleles TyrTargetΔ alleles 
1.2e male 15 17 13 
1.3f male 7 10 8 
1.3g male 9 12 11 
2.1f male 20 16 16 
2.2d male 13 17 17 
3.2g male 15 13 10 
4.3f male 12 7 6 
4.1g male 8 6 5 
5.2d male 14 18 16 
6.1e male 12 14 13 
1.1b female 21 21 4 
1.2b female 28 32 3 
3.1b female 24 23 0 
3.2e female 12 6 0 
4.1b female 27 24 1 
4.2b female 27 15 1 
4.3d female 17 20 1 
5.2c female 11 9 1 
6.1b female 8 14 2 
6.1c female 14 12 1 
Supplemental Table 2. Germline-homing individual mouse genotyping data for Vasa-Cas9-4. 
Breakdown of the ratio of inherited alleles for the offspring of the listed Vasa-Cas9-4/+ ; 
TyrgRNA-Tomato/Target mice crossed to WT. Data collated to produce Vasa-Cas-4 data in Figure 4 and 
Supplemental Figure 7. 
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Locus Primer 1 Primer 2 Primer 3 Type 
TyrgRNA-Tomato CCAGACAGCCCTTGTAATCATTAGC GGCTATCGTGGCGTTTTAGA  PCR 
TyrgRNA-Lite CCAGACAGCCCTTGTAATCATTAGC AACTTGAAAAAGTGGCACCGAG GCACCTCCTATGGTATCTGGAA PCR 
TyrTarget ACTGTTTGAGAGTCAGCAACGT TCTCTGGCCAAAACCAAGACTT  PCR/RFLP 
TyrTarget GGGTTCTGTCCTCAACTGGT TTTGATGTAAGAAGGGGAGTGGT  Large Δ PCR 
Rosa26Cas9 AAGGGAGCTGCAGTGGAGTA CCGAAAATCTGTGGGAAGTC CCATAAGGTCATGTACTGGGC PCR 
Vasa-Cas9 ATTGTACTTCAGCACAGTTTTAGAG AGTCTCCGTCGTGGTCCTTA  PCR 




















Supplemental Table 3. List of PCR primers. Shown in 5’ to 3’ orientation. 
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Supplemental Table 4. DNA sequences for generation of mouse models. Homology arms 





9.3 ADDITIONAL METHODS, RESULTS, AND DISCUSSION 
9.3.1 Sperm Sequencing 
A more in-depth analysis of Cas9 cleavage via NextGen sequencing in germline-homing gene drive 
mice was thought to be an informative experiment to perform as this approach could definitively 
show that the gene drive activity is occurring in the germline cells and is not due to a leaky promoter 
or mRNA carryover. It could also provide a more accurate measure of the rate of error-prone repair 
in comparison to WT sequence as each individual sequence read provides the same amount of 
information on a repair event as the analysis on one offspring. The exact indels and their different 
ratios could further be analysed too. 
DNA was extracted from sperm from Vasa-Cas9-2/+ ; TyrgRNA-Tomato/Target mice as per the DNA 
extraction methods section 9.2. The TyrTarget locus was amplified using primers 
5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTTAGCCAGACAGCCCTTGT-3' and 
5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTCTGGCCAAAACCAAGACT-3', and 
paired end Illumina MiSeq sequencing was performed by AGRF. Resulting data was analysed using 
CRISPResso2119 and is shown in Figure 13. 
 
Figure 13. NextGen sequencing data of TyrTarget locus in sperm from Vasa-Cas9-2/+ ; TyrgRNA-Tomato/Target mice. The dotted line 
indicates the Cas9 cleavage site. Dashes represent deletions, red boxes indicate an insertion, and a bold letter indicates a 
base change. Data shows reference sequence and number of reads for each allele resulting from error-prone repair. 










The sequencing data shows an indel formation rate of ∼20%, reflecting a similar cut rate (14.5%) to 
what was determined by genotyping offspring (Supplemental Figure 7A in section 9.2). Considering 
the rate of indels in the sperm, we can infer that the indels as discussed in the manuscript were from 
germline activity of the gene drive and not a result of any mRNA carryover. However, as female 
germline cells were not assayed, we can’t definitively conclude there was no maternal mRNA 
carryover. 
This sequencing demonstrates specific indels formed and the corresponding rate of formation are 
very predictable. A single T insertion is the most common indel in every sample at a rate of 7.74-
11.43% and a 9 bp deletion is the second most common in every sample at 1.59-2.58%. A 7 bp 
deletion is the third most common in 5 of 6 samples at 0.58-1.06%. The rest of the indel alleles occur 
at very low rates (0.55% and under), which includes 11 indels unique to particular sperm samples 
but also a further 5 indels that are present in multiple samples. 
These data present an interesting opportunity for gene drives in general. Since we know that 
resistance allele formation is a major hurdle to overcome for the effective spread in wild 
populations, so any strategies to help reduce the rate of resistance allele formation are going to be 
extremely beneficial. These data suggest a strategy to reduce that rate, if a gene drive were to be 
made with multiple, secondary gRNAs within it, each one could target one of the major resistance 
alleles based on sequencing data, therefore giving the cell another opportunity for HDR instead of 
following error-prone repair pathways. 
9.3.2 TyrgRNA-Tomato High Penetrance Lethality and TyrgRNA-Lite Mouse Model 
As briefly discussed in the mouse model generation methods in section 9.2 above, during routine 
breeding of the TyrgRNA-Tomato mice highly penetrant lethality was observed. Initially this was only seen 
in homozygotes which all died before weaning so it was assumed to be a homozygous lethal trait. 
Unfortunately, as breeding continued, spontaneous lethality occurred in hemizygotes too. The 
earliest death was at P67 and of all mice that reached this age 34% died prematurely. Stressors such 
as mating or pregnancy tended to increase the death rate. Affected mice were mostly found 
deceased showing no earlier signs of distress or illness. 
The specific cause of death is unknown, considering the subsequently generated TyrgRNA-Lite mouse 
lacking the dTomato fluorophore showed no lethality phenotype, we posited that perhaps a high 
level of dTomato was being produced under the CAG promoter, aggregating, causing complications, 
and leading to death. Extremely high levels of fluorescence were seen and the levels were so high 
such that upon autopsy internal organs were visibly redder compared to controls. Another potential 
cause of this phenotype was that upon insertion of the TyrgRNA-Tomato cassette, there was off-target 
cutting that disrupted a critical gene. However, given that the colony was established by out-crossing 
resulting in segregation of the founder’s chromosomes over several generations, this seems very 
unlikely. 
The TyrgRNA-Lite mice that were subsequently generated, although not specifically mentioned in the 
manuscript, contained a bovine growth hormone (BGH)-polyadenylation (polyA) signal in the same 
orientation as Tyr. This was intended to mimic the same effect as the 3x simian virus 40 (SV40) polyA 
signal in TyrgRNA-Tomato mice where hemizygotes would have a black coat and homozygotes would 
have a white coat. However, upon testing this system, the BGH-polyA signal was insufficient to 
terminate transcription of Tyr in homozygotes, having no effect on the coat colour. The white coat 
phenotype was not a critical aspect to the experiments however, so the experiments continued 




10 CAS12A ZYGOTIC AND GERMLINE GENE DRIVES 
10.1 INTRODUCTION 
10.1.1 Cas12a 
A gene drive is highly dependent upon what cellular repair mechanisms take priority (HDR vs. error-
prone repair),59 which is influenced by the state of the DNA after cleavage.4, 28 Cas9 DNA cleavage 
generates a DSB with two blunt DNA ends,3 we hypothesised that a gene drive employing a CRISPR 
nuclease that induced a different kind of DSB may favour the HDR pathway over error-prone repair. 
Cas12a (formerly Cpf1)120 is one such system. In contrast to Cas9, Cas12a produces a staggered cut 
that is not consistently positioned (Figure 14).120 On the non-complementary strand it has been 
shown to be 14 or 16 bp 3’ of the PAM and 23-25 bp in the same direction on the complementary 
strand.120 Further to this, there are trimming events post-cleavage which can cause the loss of up to 
4 bp on the non-complementary strand.120 All this results in a DSB with 5’ overhangs on the end of 
each strand. This may be useful in promoting HDR or at least reducing NHEJ as the DSB with 
overhangs will be in a state that potentially favours HDR and MMEJ over NHEJ, the latter of which 
proceeds with blunt ends.28 Indeed, subsequent to the design of this project, when testing targeted 
DNA integration in zebrafish there was shown to be a higher rate of HDR in comparison to Cas9.121 
 
Figure 14. Schematic outlining the differences between Cas9 and Cas12a. Cas12a requires a different gRNA (red),42 the PAM 
(green) is at the opposite end and has a different sequence (TTTN),42 and whilst the Cas9 produces a blunt cut (black 




Aside from the cleavage method, Cas12a has several significant differences from Cas9. Most 
importantly is that target sites in the gDNA require a TTTN PAM on the 5’ end of the non-
complementary strand as opposed to the NGG at the 3’ end for Cas9.42 
Cas12a also uses a different gRNA, the guide region (18-26 nt) is on the 3’ end compared to Cas9 
where it is on the 5’ end.42 Considering that Cas12a cuts at the PAM-distal region,42 any indels are far 
from the PAM where, similar to Cas9 it is less likely to be important for binding.12-14 This suggests 
Cas12a would be more likely to rebind and cut that same site again even if there are already indels 
present from a previous cleavage event. However, the relationship Cas12a has with off-target 
binding and what MMs do to the binding affinity are less understood than Cas9. The data are 
contradictory and indicate both that the bases closer to the PAM are more important and also that 
the bases along the entire gRNA binding site are equally important.120, 121 If indeed Cas12a was more 
likely to re-cut an already cut allele with indels present at the PAM-distal region, this would be 
greatly beneficial to a gene drive. Considering it is desirable to get as few indels as possible, this 
would allow the gene drive multiple chances at homing via the HDR pathway instead of a single 
error-prone repair event generating a resistance allele. 
10.2 EXPERIMENTAL DESIGN 
10.2.1 Aims 
The major aim was to develop both zygotic- and germline-homing gene drives utilising Cas12a. These 
were designed to incorporate both a split drive system and a synthetic target, keeping safety as 
paramount. The major aim is broken down into sub-aims 1, 2 and 3. 
Sub-aim 1 was to design and generate the following mouse models: A mouse expressing Cas12a 
under a germline promoter, a mouse expressing Cas12a under a zygotic promoter, a mouse 
expressing a Cas12a gRNA, and a mouse containing a synthetic target. 
Sub-aim 2 was to cross the Cas12a gRNA line, synthetic target line, and zygotic Cas12a expression 
line, then to analyse its genotype for evidence of homing. 
Sub-aim 3 was to cross the Cas12a gRNA line, synthetic target line, and germline Cas12a expression 
line, then to cross that line with WT mice and analyse the inheritance pattern for evidence of 
homing. 
10.2.2 Mouse Models 





Figure 15. Schematic showing the mouse models needed for the Cas12a gene drives. Scissors show CRISPR cut sites for 
insertion of custom DNA. Image created with BioRender.8 
The TyrTarget mouse with a synthetic gRNA binding site in intron 1 of the Tyr gene which was 
previously made for the Cas9 gene drives was re-used here. This was possible as a Cas12a TTTN 
PAM site is directly adjacent the Cas9 NGG PAM site as shown in Figure 16. 
 
Figure 16. Tyr intron 1 with TyrTarget insert. Shown are the Cas12a PAM (green) and Cas12a gRNA binding sequence (red) 
which encompasses the Cas9 PAM (blue). The Cas9 binding sequence (purple) is also shown on the complementary strand. 
TyrCas12a-gRNA-Tomato, the Cas12a version of TyrCas9-gRNA-Tomato, is a mouse that contained a U6-promoter 
driven69 Cas12a gRNA (“Tyr12a-gRNA”) that targets TyrTarget as shown in Figure 16 and is located in 
the same genomic locus as TyrTarget. It also contained a ubiquitously expressed CAG-promoter 
driven122 dTomato gene123 used as a fluorescent reporter and an SV40 late polyA signal to interrupt 
TGACCTTTACCAGCCACGATAGCCGCGCTGCCTTACA 
ACTGGaaatGGTCGGTGCTATCGGCGCGACGGAATGT 




the Tyr gene.124 This was made by cutting out the U6-Cas9-gRNA cassette present in the 
TyrCas9-gRNA-Tomato mouse and inserting in a U6-Cas12a-gRNA cassette. U6 promotes transcription by 
Pol III and a poly(T) signal terminates it, in this case TTTTT was used to ensure efficient 
termination.125 
TyrCas12a-gRNA-Lite was in the same locus and contained only the U6-Tyr12a-gRNA cassette from 
TyrCas12a-gRNA-Tomato without any other elements. This was created as an alternative to 
TyrCas12a-gRNA-Tomato due to the low penetrance lethality seen in TyrCas9-gRNA-Tomato mice as discussed in 
section 9.3.2 which emerged likely due to the dTomato protein. 
For generating Cas12a lines, a choice needed to be made between AsCas12a and LbCas12a, two 
variants with similar function and activity. At the time of making this decision, the published 
literature comparing the two was inconclusive in regards to what would be a better choice: Zhang et 
al. (2017) showed greater percentage of indel formation with LbCas12a in mouse fibroblasts and 
Toth et al. (2016) showed a slightly higher rate of HDR for LbCas12a (24% vs. 15%) in N2a mouse 
neuroblastoma cells. However, in mouse embryos, in vivo data from Kim et al. (2016) showed a 
similar number of indels were generated for each type of Cas12a, varying from 2-80%. As gene 
drives operate in vivo, this data was considered particularly relevant. Combined with data from our 
own lab, published by Robertson et al. (2018) showing that AsCas12a gave a 33% rate of indel 
formation in vivo, AsCas12a was chosen for the gene drives. 
For zygotic homing, CMV-Cas12a, a ubiquitously expressed, CMV promoter driven122 AsCas12a gene, 
randomly integrated into the mouse genome was generated. For germline homing, Vasa-Cas12a, the 
AsCas12a gene driven by the germline promoter Vasa,129 also randomly integrated into the mouse 
genome was generated. 
10.2.3 Experiments 
10.2.3.1 Zygotic-homing Gene Drive 
Figure 17 shows the design for the zygotic-homing gene drive experiment. We generated 
CMV-Cas12a/CMV-Cas12a ; TyrCas12a-gRNA-Lite/Cas12a-gRNA-Lite mice, TyrTarget/Target mice, and crossed them 
together to produce CMV-Cas12a/+ ; TyrCas12a-gRNA-Lite/Target zygotes. If homing occurred, we would 
expect a TyrCas12a-gRNA-Lite homozygote, if no homing occurred we would expect error-prone repair to 





Figure 17. Zygotic-homing Cas12a gene drive experimental design, showing relevant homologous chromosomes. Expected 
genetic outcomes shown as either homing or resistance allele formation. Image created with BioRender.8 
10.2.3.2 Germline-homing Gene Drive 
Figure 18 shows the experimental setup for the germline-homing gene drive. Vasa-Cas12a/+ ; 
TyrCas12a-gRNA-Lite/Target mice were generated as a first step. As homing rates could potentially vary 
anywhere from 0 to 100%, the schematic shown illustrates the expected genetic outcomes in those 
two extreme cases. If homing occurred with 100% efficiency, all sperm or ova in the experimental 
mice would contain the TyrCas12a-gRNA-Lite gene. Then, after crossing to a WT mouse, 100% of the 
produced embryos would be TyrCas12-gRNA-Lite/+. In contrast, if homing did not occur, 50% of the 
haploid sperm or ova in the experimental mouse would contain the TyrCas12a-gRNA-Lite gene with the 
other 50% containing TyrTarget. Then, after crossing to a WT mouse, the embryos would be on 





Figure 18. Germline-homing Cas12a gene drive experimental design, showing relevant homologous chromosomes. The 
schematic shown here illustrates the expected genetic outcomes in the two extreme cases where homing rates are either 
100% or 0%. Red sperm and ova (middle boxes) contain the TyrCas12a-gRNA-Lite gene. Red embryos (bottom) are 
TyrCas12-gRNA-Lite/+. Blue sperm and ova (middle boxes) contain the TyrTarget gene. Blue embryos (bottom) are TyrTarget/+. Image 
created with BioRender.8 
10.3 METHODS 
10.3.1 Mouse Model Generation 
C57BL/6JSah females were superovulated by injecting 5 IU Folligon® PMSG (Intervet India) followed 
by 5 IU Chorulon® hCG (Intervet India) 47.5 h later. Superovulated females were mated to male 
C57BL/6JSah mice overnight. 
The following morning presumptive zygotes were collected from oviducts in EmbryoMax® FHM 
Mouse Embryo Media (Sigma-Aldrich) and hyaluronidase (15 ng/mL) for denudation of cumulus 
cells. Presumptive zygotes were washed in EmbryoMax® FHM Mouse Embryo Media (Sigma-Aldrich), 
transferred to EmbryoMax® KSOM Mouse Embryo Media with 1/2 Amino Acids (Sigma-Aldrich) at 
37°C in 5% CO2, and screened for the presence of two pronuclei (indicating fertilisation). 
Zygotes were transferred to EmbryoMax® FHM Mouse Embryo Media under Paraffin (#107160, 




detailed in subsequent sections) buffered in pH 8 EDTA (0.05 M) and pH 7.5 Tris (0.1 M) filtered at 
0.45 µm. Zygotes were then transferred to EmbryoMax® KSOM Mouse Embryo Media with 1/2 
Amino Acids under Paraffin at 37°C in 5% CO2. Either the same day or the following, zygotes were 
washed in EmbryoMax® FHM Mouse Embryo Media (Sigma-Aldrich) before being transferred 
unilaterally into the oviducts of pseudopregnant CD1 female mice and allowed to come to term. 
10.3.1.1 TyrTarget 
This mouse had already been generated for the Cas9 gene drive paper (see the design and 
generation of homing system results in section 9.2). 
10.3.1.2 TyrCas12a-gRNA-Lite 
The Cas9 “Tyr-gRNA” guide targeting Tyr intron 1 (5’-ATCAGGCAATCATGTAATAA-3’) was 
designed using the Zhang lab tool at http://crispr.mit.edu/14 (now decommissioned). Plasmid 
containing complete Tyr-gRNA sequence was generated in pSpCas9(BB)-2A-Puro (PX459) V2.0 
(Addgene; 62988)130 with oligos purchased from IDT (5’-GGCTATCGTGGCGTTTTAGA-3' and 
5’-AAACTTATTACATGATTGCCTGATC-3'). Tyr-gRNA dsDNA was amplified with the addition of 
a T7 promoter using oligos purchased from IDT (5’-TTAATACGACTCACTATAGATCAGGCAATCA-
TGTAATAA-3' and 5’-AAAAGCACCGACTCGGTGCC-3'). Tyr-gRNA was generated using 
HiScribe™ T7 Quick High Yield RNA Synthesis Kit (NEB) and purified using RNeasy Mini Kit (Qiagen). 
U6-Cas12a-gRNA ssDNA described in Figure 15 for the TyrCas12a-gRNA-Lite line purchased from IDT as a 
Megamer®: 
        1 TAAATCTCTG GCCAAAACCA AGACTTATTA TTCAGGATCT TCAAGAGAAA GTGCTGAGAT 
       61 AATTCACTAA GTATCAGAGA TGACCTTTAA AAAAAGGCAG CGCGGCTATC GTGGCTGGAT 
      121 CTACAAGAGT AGAAATTACG GTGTTTCGTC CTTTCCACAA GATATATAAA GCCAAGAAAT 
      181 CGAAATACTT TCAAGTTACG GTAAGCATAT GATAGTCCAT TTTAAAACAT AATTTTAAAA 
      241 CTGCAAACTA CCCAAGAAAT TATTACTTTC TACGTCACGT ATTTTGTACT AATATCTTTG 
      301 TGTTTACAGT CAAATTAATT CCAATTATCT CTCTAACAGC CTTGTATCGT ATATGCAAAT 
      361 ATGAAGGAAT CATGGGAAAT AGGCCCTCTT ACATGATTGC CTGATAGAAA AAATGATTAC 
      421 ACACACACAA AAAAATCTTC AGTTGCTTAA ATTTTAAACG TTGCTGACTC TCAAAC 
0.75 µL PNA Bio SpCas9 protein (1 µg/µL) and 0.75 µL Tyr-gRNA (500 ng/µL) were incubated 10 min 
on ice, then mixed with U6-Cas12a-gRNA ssDNA (final concentration 10 ng/µL) to a total volume of 
15 µL with buffer as detailed in section 10.3.1. This mixture was injected into zygotes as detailed in 
section 10.3.1. 
10.3.1.3 TyrCas12a-gRNA-Tomato 
The Cas9 “U6-gRNA1” and “U6-gRNA2” guides targeting the U6-Cas9-gRNA cassette in the 
TyrCas9-gRNA-Tomato mouse (5’-AGGACGAAACACCGGCAGCG-3’ and 5’-CGGTGCTTTTTGCTAGCG-
GC-3’) were designed using the GT-Scan tool at https://gt-scan.csiro.au/gt-scan.16 Two separate 
plasmids containing complete U6-gRNA sequences were generated in pSpCas9(BB)-2A-Puro (PX459) 
V2.0 (Addgene; 62988)130 with oligos purchased from Sigma-Aldrich (5’-ACCGAGGACGAAACACC-
GGCAGCG-3' paired with 5’-AAACCGCTGCCGGTGTTTCGTCCTC-3' and 5’-ACCGCGGTGCT-
TTTTGCTAGCGGC-3' paired with 5’-AAACGCCGCTAGCAAAAAGCACCGC-3' for the two 
respective gRNAs/plasmids). U6-gRNA1 and U6-gRNA2 dsDNA were amplified with the addition of a 
T7 promoter using oligos purchased from Sigma-Aldrich/IDT (5’-TTAATACGACTCACTATAGAGG-




ACGACTCACTATAGCGGTGCTTTTTGCTAGCGGC-3' paired with 5’-AAAAGCACCGACTCGGTG-
CC-3' for the two respective gRNAs). U6-gRNAs were generated using HiScribe™ T7 Quick High 
Yield RNA Synthesis Kit (NEB) and purified using RNeasy Mini Kit (Qiagen). 
U6-Cas12a-gRNA ssDNA described in Figure 15 for the TyrCas12a-gRNA-Tomato line purchased from IDT as a 
Megamer®: 
        1 CCAAAACCAA GACTTATTAT TCAGGATCTT CAAGAGAAAG TGCTGAGATA ATTCACTAAG 
       61 TATCAGAGAT GACCTTTACC AGCCAAAAAA GGCAGCGCGG CTATCGTGGC TGGATCTACA 
      121 AGAGTAGAAA TTACGGTGTT TCGTCCTTTC CACAAGATAT ATAAAGCCAA GAAATCGAAA 
      181 TACTTTCAAG TTACGGTAAG CATATGATAG TCCATTTTAA AACA 
0.75 µL PNA Bio SpCas9 protein (1 µg/µL) and 0.75 µL U6-gRNA1 (500 ng/µL) were incubated 10 min 
on ice. 0.75 µL PNA Bio SpCas9 protein (1 µg/µL) and 0.75 µL U6-gRNA2 (500 ng/µL) were incubated 
10 min on ice. These were mixed with U6-Cas12a-gRNA ssDNA (final concentration 10 ng/µL) to a 
total volume of 15 µL with buffer as detailed in section 10.3.1. This mixture was injected into a mix 
of TyrCas9-gRNA-Tomato/+ and WT C57BL/6J zygotes as detailed in section 10.3.1. The mix of zygote 
genotypes was due to TyrCas9-gRNA-Tomato/+ being used as one parent because of the high rate of 
spontaneous deaths of TyrCas9-gRNA-Tomato homozygotes due to unknown reasons as detailed in section 
9.3.2. 
10.3.1.4 CMV-Cas12a 
Although this was primarily an attempt at random integration, a gRNA targeting Rosa26 (“Rosa26-
gRNA”) was also used to promote integration at that locus and potentially encourage activation of 
DNA repair machinery to facilitate more integrations. Rosa26-gRNA design was previously published 
(5’-ACTCCAGTCTTTCTAGAAGA-3’).131 Plasmid containing complete Rosa26-gRNA sequence was 
generated in pSpCas9(BB)-2A-Puro (PX459) V2.0 (Addgene; 62988)130 with oligos purchased from 
Sigma-Aldrich (5’-CACCGACTCCAGTCTTTCTAGAAGA-3' and 5’-AAACTCTTCTAGAAAGACT-
GGAGTC-3'). Rosa26-gRNA dsDNA was amplified with the addition of a T7 promoter using oligos 
purchased from Sigma-Aldrich/IDT (5’-TTAATACGACTCACTATAGACTCCAGTCTTTCTAGAAG-
A-3' and 5’-AAAAGCACCGACTCGGTGCC-3'). Rosa26-gRNA was generated using HiScribe™ T7 
Quick High Yield RNA Synthesis Kit (NEB) and purified using RNeasy Mini Kit (Qiagen). 
The CMV-Cas12a construct in its entirety was already present in pY010 (pcDNA3.1-hAsCpf1) 
(Addgene; 69982)42, this was digested with MfeI and DraIII to isolate CMV-AsCas12a-BGH(polyA) as 





Figure 19. Generation of the CMV-Cas12a construct. pY010 plasmid42, black triangles indicate restriction sites. Image created 
with BioRender.8 
0.75 µL PNA Bio SpCas9 protein (1 µg/µL) and 0.75 µL Rosa26-gRNA (500 ng/µL) were incubated 10 
min on ice, then mixed with CMV-Cas12a dsDNA (final concentration 3 ng/µL) to a total volume of 15 
µL with buffer as detailed in section 10.3.1. This mixture was injected into zygotes as detailed in 
section 10.3.1. 
10.3.1.5 Vasa-Cas12a 
Gibson assembly fragments were constructed as follows, shown in Figure 20. pStart-K (Addgene; 
20346)132, a small, low-copy number plasmid functioning as the backbone was digested with EcoRI. 
The Vasa-β-globin-II fragment was amplified from pVasa-Cre (Addgene; 15885)129 using primers 
5’-GCTTTAAAGGAACCAATTCAGTCGACTGGATCCGGTACCGTGTGCCACCATGCCTGG-3' and 
5’-AAGCCCTCGAACTGTGTCATGGAGCTGTAGGAAAAAGAAGAAGG-3'. The AsCas12a-
BGH(polyA) fragment was amplified from pY010 (pcDNA3.1-hAsCpf1) (Addgene; 69982)42 using 
primers 5’-CTTCTTTTTCCTACAGCTCCATGACACAGTTCGAGGGCTTTAC-3' and 5’-TACAAG-
AAAGCTGGGTCTAGATATCTCGAGTGCGGCCGCGGTCGACCGCCTCAGAAGCCATAGAGC-3', the 
latter included the addition of a SalI restriction site. After Gibson assembly and transformation in 
MAX Efficiency™ DH5α™ Competent Cells (Invitrogen), pSK-VCas12a was expanded with PureLink™ 







Figure 20. Generation of the Vasa-Cas12a construct. Black triangles indicate restriction sites. Half arrows indicate PCR 
primers. Image created with BioRender.8 
0.75 µL PNA Bio SpCas9 protein (1 µg/µL) and 0.75 µL Rosa26-gRNA (500 ng/µL) were incubated 10 
min on ice, then mixed with Vasa-Cas12a dsDNA (final concentration 3 ng/µL) to a total volume of 15 
µL with buffer as detailed in section 10.3.1. This mixture was injected into zygotes as detailed in 
section 10.3.1. 
10.3.2 In Vivo Cleavage Assessment 
The Cas12a guide Tyr12a-gRNA targeting TyrTarget (5’-CCAGCCACGATAGCCGCGCTGCCT-3’) was 
analysed using the GT-Scan tool at https://gt-scan.csiro.au/gt-scan.16 Plasmid containing CMV-
AsCas12a and complete Tyr12a-gRNA sequence was generated in pY026 (Addgene; 84741)133 with 
oligos purchased from Sigma-Aldrich (5’-AGATCCAGCCACGATAGCCGCGCTGCCTT-3' and 
5’-AAAAAAGGCAGCGCGGCTATCGTGGCTGG-3'), and expanded with PureLink™ HiPure Plasmid 
Midiprep Kit (Invitrogen). 
The same process to prepare for microinjection of zygotes as described in 10.3.1 was performed 
except using TyrTarget/Target mice instead of C57BL/6JSah and the injection mix contained only 
pY026Tyr12a-gRNA plasmid (100 ng/µL) in the same buffer. 
10.3.3 Sample Collection 
For colony genotyping, tissue was collected via ear notching live mice. For zygotic-homing gene drive 




were culled at ∼P0 and tail tissue was collected for DNA extraction. For genotyping the fetal 
offspring of male germline-homing gene drive mice and fetuses for the in vivo cleavage assay 
(section 10.3.2), pregnant females were culled at ∼E12.5 and tail tissue was collected from fetuses. 
For genotyping the blastocyst offspring of female germline-homing gene drive mice, females were 
superovulated by injecting 5 IU Folligon® PMSG (Intervet India) followed by 5 IU Chorulon® hCG 
(Intervet India) 47.5 h later at ∼5 PM. The following morning, oviducts were collected from females 
into M2 medium (#M7167, Sigma-Aldrich) and kept at 4 °C. Cauda epididymides were collected from 
a C57BL/6J male into M2 medium and kept at 4 °C. IVF was performed as per the Online Manual for 
CARD Mouse Reproductive Technology sections “In Vitro Fertilization using Epididymal Sperm 
Transported at Cold Temperature”134 and “In Vitro Fertilization (IVF)”135. Embryos were cultured in 
mHTF (#KYD-008-02-EX-X5, United Bioresearch) under Paraffin (#107160, Merck Millipore) at 37°C in 
5% CO2/5% O2 overnight. All 2-cell embryos were transferred to fresh culture media in the same 
conditions and incubated for 72-84 h. Embryos that developed a blastocoel were washed in M2 
medium and transferred with 1 µL M2 medium into 9 µL MQ H2O. 
For mRNA transcription data, whole testes, ovaries, and spleens were collected from adult mice. 
10.3.4 Sample Extraction 
For ear notch/tail tissue DNA extraction, gDNA was extracted from samples using High Pure PCR 
Template Preparation Kit (Roche), KAPA Express Extract kit (Roche), or MyTaq™ Extract-PCR Kit 
(Bioline). 
For blastocyst DNA extraction, a blastocyst lysis buffer base was made with 2 mL pH 8.3 Tris-HCl (1 
M), 2 mL KCl (1 M), 40 µL 2% gelatin, 90 µL Polysorbate 20, and 5.87 mL MQ H2O, stored at RT. For 
each extraction, blastocyst lysis buffer was made with 125 µL blastocyst lysis buffer base, 2 µL tRNA 
from baker’s yeast (Sigma-Aldrich), and 7.75 µL Proteinase K (20 mg/mL) (Thermo Scientific). 10 µL 
of blastocyst lysis buffer was then added to blastocysts before heating to 56 °C for 10 min, then 
inactivated at 95 °C for 10 min. 
For RNA extraction, acid guanidinium thiocyanate-phenol-chloroform RNA extraction was performed 
on testes, ovaries, and spleens with clean-up performed using RNeasy Mini/Micro kit (Qiagen) in 
conjunction with RNase-Free DNase Set (Qiagen). 
10.3.5 Genotyping 
TyrTarget and TyrCas12a-gRNA-Lite mice were genotyped using primers 5’-CCAGACAGCCCTTGTAATCAT-
TAGC-3’ and 5’-TCTCTGGCCAAAACCAAGACTT-3’, giving a 376 bp band for WT, 399 bp for 
TyrTarget, and 675 bp TyrCas12a-gRNA-Lite. 
TyrTarget/+ mice were screened for TyrTarget cleavage using a modified restriction fragment length 
polymorphism (RFLP) protocol as follows. A 20 µL PCR around the region was performed with 
primers 5’-ATACACAGCAGGCTTTAACTCTTTT-3’ and 5’-GGATCTTCAAGAGAAAGTGCTGAG-
A-3’, giving a 202 bp band for TyrTarget and a 179 bp band for WT. 10 µL was added to a 20 µL T7 
Endonuclease I (NEB) digestion for 15 min, 10 µL of that reaction was added to a 20 µL TseI (NEB) 
digestion for 15 min, loaded onto a 2.5% agarose gel, and ran at 100 V for 90 min. Due to the very 
small difference in size between TyrTarget PCR products and WT PCR products, a complicated mix of 
heteroduplexes formed during amplification. The added step of including an endonuclease digested 
all the heteroduplexes to give a cleaner band pattern before restriction digest. The TseI binding site 




Some TyrTarget/+ mice were screened for TyrTarget cleavage using a combination of Sanger sequencing 
(with primers 5’-CCAGACAGCCCTTGTAATCATTAGC-3’ and 5’-TCTCTGGCCAAAACCAAGAC-
TT-3’) and Tracking of Indels by DEcomposition (TIDE)136/Inference of CRISPR Edits (ICE)137 analysis. 
These tools require a WT Sanger sequencing trace to use as a background for comparison. As the 
TyrTarget and WT alleles only differ by 23 bp, they are hard to separate on a gel for extraction and 
independent sequencing. Instead, they were sequenced together, and TyrTarget/Target DNA was used as 
background which results in a “false” 23 bp deletion showing up for all TIDE/ICE analyses. 
TyrCas12a-gRNA-Tomato mice were sequenced using primers 5’-ATGCAGAAGAAGACCATGGGCT-3’ and 
5’-GCACCTCCTATGGTATCTGGAA-3'. 
Routine genotyping for CMV-Cas12a mice was performed using primers 5’-AAGAATCACGAGAGC-
CGCAA-3’, 5’- GATTGGAGATGCCGTTCTGC-3’, 5’-AAGGGAGCTGCAGTGGAGTA-3’, and 
5’-CCGAAAATCTGTGGGAAGTC-3’, giving a 297 bp band for WT and CMV-Cas12a and 622 bp for 
CMV-Cas12a. F0 genotyping was performed using primers 5’-TGTACGGGCCAGATATACGC-3’ and 
5’-GCCCTCGAACTGTGTCATGG-3’, giving a 735 bp band for CMV-Cas12a and no band for WT. 
qPCR was performed to determine zygosity using primers 5’-AAGAATCACGAGAGCCGCAA-3’/ 
5’-AGGATGAAGTCGCCGGTTTT-3’ for CMV-Cas12a, and 5’-AGGATGAAGTCGCCGGTTTT-3’/ 
5’-CCTCTCAGACGGTGGAGTTATATT-3’ for sox1 as a reference gene. 










Table 1. Paired primers for sequencing CMV-Cas12a. 
Vasa-Cas12a mice were genotyped using primers 5’-GCACGTGCAGCCGTTTAAG-3’, 5’- CTGG-
CGTTGATGGGGTTTTC-3’, 5’-GGCTGATCCGTGTGGAGTAT-3’, and 5’-AGGGCCACAACAGT-
AAATGG-3’, giving a 647 bp band for WT and Vasa-Cas12a and 719 bp for Vasa-Cas12a. F0 
genotyping was performed using the first 2 primers which only gave the 719 bp band. qPCR was 
performed to determine zygosity using the same primer set as for CMV-Cas12a above. 










Table 2. Paired primers for sequencing Vasa-Cas12a. 






cDNA was generated using High-Capacity RNA-to-cDNA™ Kit (Applied Biosystems). 
mRNA levels were quantitated using primers 5’-AAGAATCACGAGAGCCGCAA-3’/5’-AGGATGA-
AGTCGCCGGTTTT-3’ targeting AsCas12a, and primers 5’-TGATGGCACTGGCCCCAACAT-3’/ 
5’-GCGCCCTCCTTAGTAGCCCAC-3’ targeting the reference gene eukaryotic elongation factor 2 
(eEF2). 
10.4 RESULTS 
10.4.1 Mouse Model Generation 
10.4.1.1 TyrCas12a-gRNA-Lite 
Of 39 pups born from CRISPR microinjection, 2 contained the complete insert in Tyr intron 1 (Figure 
21). Sanger sequencing of the entire insert revealed one mouse had a MM and the second had a 
dual base call. Subsequent breeding of the latter showed only the correct base was passed on. 
 
Figure 21. Representative gel showing genotyping of TyrCas12a-gRNA-Lite F0 mice. Samples 2.1d and 2.1g show a band matching 
the expected size. 
10.4.1.2 TyrCas12a-gRNA-Tomato 
3 of 4 pups born from microinjection were positive for TxRed fluorescence in ear notches, confirming 
the TyrCas9-gRNA-Tomato allele had been inherited from the heterozygous parent. However, Sanger 
sequencing revealed that no insertions were detected and no CRISPR cleavage had taken place. Only 
one microinjection session was performed to attempt generation of this line before it was decided 
not to proceed. The number of spontaneous deaths of both homozygotes and hemizygotes of the 
TyrCas9-gRNA-Tomato line was increasing (as per section 9.3.2) and the reason was not known. One 
possible explanation was a high rate of production of dTomato protein with associated toxicity. Due 
to this risk it was decided to complete the Cas12a experiments without the aid of a fluorescent 
marker and to use the TyrCas12a-gRNA-Lite line exclusively. 
10.4.1.3 CMV-Cas12a 
Of 15 pups born from CRISPR microinjection, genotyping revealed that 3 contained the insert (Figure 
22). Although PCR and Sanger sequencing of the Rosa26 target site showed the formation of indels, 
the CMV-Cas12a construct was not inserted there and all were in random locations. The complete 





Figure 22. Representative gel showing genotyping of CMV-Cas12a F0 mice. The plasmid pY010 contained the full 
CMV-Cas12a construct and was used as a positive control. Samples 1.1c and 2.1b show a clear band matching the positive 
control. 
One of the F0 CMV-Cas12a mice failed to transmit the gene after screening 39 pups, indicating it was 
a low-level mosaic and likely no germ cells contained the CMV-Cas12a construct. Another F0 female 
was unable to be fully characterised as it died due to birthing issues with its first litter. 
The third F0 CMV-Cas12a mouse successfully transmitted and was determined to have integrated on 
the X-chromosome. This was confirmed by 2 pieces of data: No males that could potentially be 
homozygous were homozygous (n=72) and the hemizygous offspring of male CMV-Cas12a crossed 
to WT females were always female (n=30). 
Cas12a mRNA levels were characterised in the testes, ovaries, and spleen by RT-qPCR (Figure 23). 
Significant background amplification could be seen, likely primer-dimer formation as can be inferred 
from the WT melt curves from all tissues which exhibit a lower peak in comparison to the CMV-
Cas12a testis tissue melt curve where the highest level of mRNA can be seen. Very low levels of 
Cas12a mRNA can be seen in the ovary and both male and female spleens as evidenced by their melt 





Figure 23. Characterisation of Cas12a mRNA levels in CMV-Cas12a mice by RT-qPCR. Left: Relative quantification of mRNA 
(with 95% CI). Top right: WT melt curves from all tissues. Middle right: CMV-Cas12a testis tissue melt curves. Bottom right: 
CMV-Cas12a ovary and both male and female spleen melt curves. 
10.4.1.4 Vasa-Cas12a 
Of 23 pups born from CRISPR microinjection, 7 contained the insert (4 male/3 female, Figure 24). 
The Rosa26 target site again only showed indels, so all were in random locations. The β-globin-II, 
Cas12a, and BGH polyA sequences were verified by Sanger sequencing in the males and colonies 
were established for each (Vasa-Cas12a-A, Vasa-Cas12a-B, Vasa-Cas12a-C, and Vasa-Cas12a-D). The 




















































































































Figure 24. Representative gel showing genotyping of Vasa-Cas12a F0 mice. The plasmid pSK-VCas12a (Figure 20) contained 
the full Vasa-Cas12a construct and was used as a positive control. Samples 1.1d, 1.2a, 1.2d and 2.1b show clear bands 
matching the positive control. 
Cas12a mRNA levels were characterised in testes, ovaries, and spleens by RT-qPCR in all 4 lines 
(Figure 25). Vasa-Cas12a-D was the first to be characterised, using the CMV-Cas12a line as a positive 
control, as CMV-Cas12a mRNA levels were very low in comparison, Vasa-Cas12a-D was used as a 
positive control for testing lines A-C. 
Vasa-Cas12a-D was rejected for experimental use as there was a low level of background expression 
in all tissue types, this was not seen in any of the other 3 lines. Vasa-Cas12a-B was also rejected as it 
had a much lower level of expression in testes. None of the lines had any substantial expression in 
ovaries, an unexpected outcome given the expression of Vasa-Cre from the same promoter in 
Gallardo et al. (2007), although similar to what was seen in Vasa-Cas9 lines as discussed in the 
germline homing results in section 9.2. Experimental crosses were performed with lines derived 






Figure 25. Relative quantification of cas12a mRNA levels in 4 different transgenic lines of Vasa-Cas12a mice by RT-qPCR 
(with 95% CI). 
10.4.2 Experimental Results 
10.4.2.1 In Vivo Cleavage Assessment 
The in vivo effectiveness of Cas12a with Tyr12a-gRNA to cleave TyrTarget needed to be tested in a 
context that would be as similar to the gene drive mice as possible (see Figure 17 and Figure 18). To 
this end, microinjection of a plasmid containing CMV-Cas12a and U6-Tyr12a-gRNA was performed 
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no indels were detected. Experimental crosses were continued despite this data as it could not be 
definitively concluded that indels were being created and repaired. It was also possible that delivery 
of the CRISPR components in plasmid form meant Cas12a and the gRNA were not produced quick 
enough or in sufficient quantity before being degraded or lost. 
10.4.2.2 Zygotic Homing 
To assess homing in the zygote, we generated 35 CMV-Cas12a/+ ; TyrCas12a-gRNA-Lite/Target mice. The 
TyrTarget locus was analysed via Sanger sequencing for all 35 mice and no cleavage activity was 
detected. This was confirmed further by Sanger sequencing trace analysis with TIDE136 and ICE137 to 
identify potential low-level cleavage and mosaicism. As DSB repair in zygotes often generates large 
(>100 bp) deletions,36 we amplified TyrTarget using primers distant from the cleavage site but did not 
detect large deletions (Figure 26). 
 
Figure 26. Large deletion genotyping. Representative PCR showing no detectable large deletions around TyrTarget in 4 CMV-
Cas12a/+ ; TyrCas12a-gRNA-Lite/Target mice. The only band is the expected ∼4 kb for no deletion, TyrCas12a-gRNA-Lite and TyrTarget 
bands are not different enough in size to be separated on this gel. 
10.4.2.3 Germline Homing 
To assess germline homing, Vasa-Cas12a-A/+ ; TyrCas12a-gRNA-Lite/Target mice were generated and crossed 
to WT partners. For female Vasa-Cas12a-A/+ ; TyrCas12a-gRNA-Lite/Target mice,  blastocysts were collected 
and genotyped instead of embryos. This was done in an attempt to allow a greater number of 
offspring to be genotyped at a quicker rate. 
Altogether, 93 fetuses from 4 Vasa-Cas12a-A/+ ; TyrCas12a-gRNA-Lite/Target males and 53 blastocysts from 
3 Vasa-Cas12a-A/+ ; TyrCas12a-gRNA-Lite/Target females were screened. If homing was occurring, we would 
expect greater than 50% of these offspring to contain the TyrCas12a-gRNA-Lite allele and if no homing was 
occurring it would remain at 50% (Figure 18). No significant change (χ2 goodness of fit) from the 
Mendelian inheritance ratio of 50% TyrCas12a-gRNA-Lite alleles occurred in either males (49.5%, p=1.0) or 





Figure 27. Germline-homing genotyping data. Bar graph showing the percentage of different alleles in the offspring of the 
gene drive mice Vasa-Cas12a-A/+ ; TyrCas12a-gRNA-Lite/Target and Vasa-Cas12a-C/+ ; TyrCas12a-gRNA-Lite/Target. Total number of 
offspring shown in columns. 
To assess the second Vasa-Cas12a line used, Vasa-Cas12a-C/+ ; TyrCas12a-gRNA-Lite/Target mice were also 
generated and mated with WT partners. For female Vasa-Cas12a-C/+ ; TyrCas12a-gRNA-Lite/Target mice, 
pups were collected for genotyping instead of blastocysts or embryos. This was done so they would 
not have to be culled and could continue producing offspring to allow a higher number of offspring 
from each female. 
133 fetuses from 4 Vasa-Cas12a-C/+ ; TyrCas12a-gRNA-Lite/Target males and 72 pups from 2 Vasa-Cas12a-
C/+ ; TyrCas12a-gRNA-Lite/Target females were screened. No significant change (χ2 goodness of fit) from the 
Mendelian inheritance ratio of 50% TyrCas12a-gRNA-Lite alleles occurred in either males (45.9%, p=0.38) 
or females (54.2%, p=0.56) as shown in Figure 27. 
To assess the cleavage activity of both lines, a combination of Sanger sequencing, TIDE136/ICE137 
analysis (Figure 28) and RFLP (Figure 29) was performed around the TyrTarget site in the offspring of all 
Vasa-Cas12a-A/+ ; TyrCas12a-gRNA-Lite/Target and Vasa-Cas12a-C/+ ; TyrCas12a-gRNA-Lite/Target mice. No cleavage 
was seen in female offspring of either line and only very low rates in the males (4.3% and 4.2%, 


































Figure 28. Example TIDE analysis. Shown are results of a single offspring of a WT mouse crossed to Vasa-Cas12a/+ ; 
TyrCas12a-gRNA-Lite/Target. TyrTarget/Target DNA is used as the background, which shows the inherited WT allele as a 23 bp deletion. A 
6 bp deletion is also seen. Image generated with TIDE.136 
 
Figure 29. Example RFLP analysis of TyrTarget for detection of indels. Digestion with TseI (as indicated) and T7 Endonuclease I 
(all samples), black arrows show expected uncut bands due to destruction of TseI site indicating presence of an indel, red 
arrows show cut bands due to intact TseI site and thus no indel. Samples from embryo 110 and 115 show clear extra bands 
matching the TyrTarget/+ control without TseI, indicating the presence of indels in both samples. 
 
Figure 30. Tally of TyrTarget alleles in offspring of the two Vasa-Cas12a gene drive lines. The columns show the number of 
indels (TyrTargetΔ) and the number of uncut alleles (TyrTarget). The cut rate shown as percentage of TyrTarget alleles with indels is 


























































































One further point of difference between the Cas9 and Cas12a constructs is the nuclear localisation 
signals (NLS’s) utilised. The Cas9 constructs contained 5’ SV40 NLS’s and 3’ nucleoplasmin NLS’s, 
whereas the Cas12a constructs contained only 3’ nucleoplasmin NLS’s. It’s possible that this was 
leading to a lower level of Cas12a in the nucleus compared to Cas9 but this is unlikely considering 
previously reported comparisons between these different NLS configurations with Cas9 didn’t lead 
to any significant differences in cleavage rates.138 
Moving away from the endonucleases themselves, another important difference between the 
Cas12a and Cas9 systems is the gRNA and associated transcription levels of that gRNA. A recent 
paper by Gao et al. (2018) investigated transcription of gRNAs under the U6 promoter and what 
effect that had on the gRNA product. The first thing to note is that traditionally a thymine (T)-stretch 
of T4 (4 Ts) or more has been used to terminate U6 transcription125 and in both the Cas12a and Cas9 
systems in this thesis a T5 was used. Gao et al. (2018) found that a T6 was required to completely 
terminate transcription, any less and there would be increasing amounts of read-through transcripts 
that did not terminate until they found another poly-T signal further downstream. 
The above has the potential to reduce the average binding affinity of the gRNA for Cas12a and the 
subsequent cleavage efficiency. Secondary structure formation in the gRNA when it is longer or a 
decreased binding efficiency from the longer gRNAs are potential mechanisms here. However, a 
more important discovery was made in that even when a T6 is present, a variable number of uracil 
bases are left on the 3’ end of the gRNA.139 In the case of T5 it is anywhere from 1 to 5 uracils.139 
Even this small addition of 1-5 uracils to the end of the guide portion of the 3’ end of the Cas12a 
gRNA was enough to decrease the cleavage efficiency.139, 140 This decrease in cleavage efficiency was 
not seen for Cas9,139 likely because the guide region of the Cas9 gRNA is present at the 5’ end 
instead of the 3’ end like Cas12a gRNAs where the poly-U tail is present.139, 140 
The above features of U6 transcription are likely a significant contributor to the differences seen 
between Cas9 and Cas12a cleavage. This can potentially be accounted for in future experiments by 
not relying on the poly-T termination of U6 transcription and instead using a more robust method 
such as the insertion of a hepatitis delta virus (HDV) ribozyme sequence to cleanly cleave the Cas12a 
gRNA product directly after the guide sequence.139, 140 
Setting aside any problematic differences with gRNA expression between the two endonucleases, 
although the Cas9 and Cas12a guides target the same 20-24 bp sequence, they do target different 
strands. That, along with inherent differences between the endonucleases mean they would need to 
be tested in more controlled and isolated conditions to assess whether Cas9 simply cuts more 
efficiently at that site regardless of promoters and expression levels. 
The final factor to account for is what repair pathways predominate when cleavage occurs within the 
zygote or germline tissue. The Cas9 data definitively informed us that even when there is a high rate 
of cleavage and under a ubiquitous promoter, there were still some cases where no indels were 
found. This cannot be unequivocally equated with the term cleavage efficiency as it’s been used in 
this thesis, as the endonuclease may indeed be cleaving the DNA but the cellular repair mechanisms 
may also be perfectly repairing these DSBs so that when the cut site is analysed there is no evidence 
of cleavage. The differences in the type of DSB that is produced by Cas9 (blunt) vs. Cas12a 
(staggered) may also greatly influence this. It is possible that because Cas12a creates a staggered 
DSB with single-stranded overhangs the DNA is in a state that favours non-NHEJ repair processes,28 
affording a greater probability of the DSB being perfectly repaired unlike Cas9. This is something that 
needs to be investigated further independent of a gene drive system however, as not enough 

































































































The difference in expression and activity levels of Cas9 and Cas12a between males and females was 
unexpected. This difference was observed across all four Vasa-Cas12a lines (Figure 25), both Vasa-
Cas9 lines (Supplemental Figure 6A in section 9.2), and an additional Vasa-Cas9 line that was not 
used (Figure 31). The Vasa promoter fragment used for all of these lines was previously 
characterised by Gallardo et al. (2007) where it was used to drive expression of Cre, also randomly 
integrated into the mouse genome. Expression levels of Vasa-Cas9 or Vasa-Cas12a cannot be 
compared directly to Vasa-Cre in Gallardo et al. (2007) as northern blots and β-galactosidase assays 
were used to check and localise expression. A northern blot is semi-quantitative however and the 
analysis of Cre expression through a northern blot did indicate very similar levels of Cre mRNA in 
both the testes and ovaries. Therefore, it is unlikely that the difference in expression levels between 
males and females seen in Vasa-Cas12a and Vasa-Cas9 lines is due to the Vasa promoter fragment. 
The Vasa-Cre construct does differ somewhat however, it contains an SV40 polyA signal whereas the 
Vasa-Cas9/Cas12a constructs utilise BGH polyA signals instead. This leaves open the possibility that 
there were sex-specific differences in rates of mRNA degradation leading to higher mRNA levels in 
testes. Considering previous studies have shown that the BGH polyA signal leads to higher levels of 
mRNA than the SV40 polyA signal147 this is an unlikely explanation. 
  
Figure 31. Characterisation of cas9 mRNA levels in P21 Vasa-Cas9-5 mice by RT-qPCR (with 95% CI). 
Another potential explanation for the sex bias seen in expression levels is position effect. 
Considering all the Vasa mice were integrated into the mouse genome at random locations, it is 
possible that the localised chromatin state or nearby regulatory elements are downregulating 
expression in females. However, considering that 7 different Vasa mice were tested in this thesis, all 
of them would likely be randomly integrated at different loci, it seems unlikely that the same kind of 
female-specific downregulation would be occurring in all the lines. It is also possible the Vasa-Cre 
line used by Gallardo et al. (2007) was the exception in that it showed similar expression between 
sexes as there were an additional 7 Vasa-Cre lines generated for the paper that were not discussed 
and they possibly could have had similar expression patterns to the Vasa lines generated in this 
thesis. 
Perhaps more important than the lack of activity in the female germline is the complete lack of 
homing seen in the males. Considering that Vasa-Cas9 expression levels were high and showed a 









































expected. The same effect (lack of male homing) was reported by Grunwald et al. (2019) but not by 
any of the insect papers. Considering how critical it is to have a low rate of error-prone repair to 
avoid generation of resistance alleles (as discussed in section 6.6), this is likely the most important 
finding to be taken from the work performed in this thesis. It tells us the Vasa promoter fragment is 
not a suitable promoter and likely does not activate the gene drive at a time where HDR is likely to 
occur in males, instead promoting error-prone repair pathways. 
The timing of expression under the Vasa promoter coupled with sex differences in embryo 
development provides some insight into why Vasa-driven gene drives in mice may only be viable for 
homing in females. Although endogenous Vasa is first detected between E10.5-11.5 in both sexes,148 
the Vasa promoter fragment used within this thesis was initially demonstrated to induce expression 
between E15-18 in testes and before P3 in ovaries.129 A later study indirectly showed that expression 
in ovaries was induced between E14.5-16.5, the same approximate window as in the testes.149 
Stages of spermatogenesis and oogenesis relative to embryonic days (days post-fertilisation) are 
shown in Figure 32. In the testes, the gonocytes (spermatogonial stem cell progenitors) proliferate 
until P8.5 when they enter meiosis (leptotene).150 This means there is approximately 14.5 days of 
activity of any Vasa-controlled gene drive that occurs during which the gonocytes are undergoing 
mitosis. Considering that during the normal cell cycle HDR can generally only occur in S and G2 
phases and even then, isn’t common (as discussed in 6.1.7), these are not ideal conditions for 
homing. 
 
Figure 32. Spermatogenesis (top) and oogenesis (bottom) in mice. Start of expression of endogenous Vasa (green box) and 
the Vasa promoter fragment (orange box). PGCs, primordial germ cells. SG, spermatogonia. SSC, spermatogonial stem cells. 
LZ, leptotene/zygotene. Pach, pachytene. Image modified from Hilz et al. (2016). 
Contrastingly, in the ovaries, the PGCs (oocytes) have already entered meiosis at E13.5 and 
homologous chromosomes have paired up by E16.5 when the oocytes enter pachytene.150 It should 
be noted that the E16.5 timepoint coincides with the first timepoint where evidence of expression 




a further ⁓25.5 days where the homologous chromosomes are bound together until it reaches P21 
and meiosis I rapidly completes.150 With this data, we can hypothesise that during this lengthy period 
there could be an increase in HDR simply due to the proximity of the homologous chromosomes 
considering that they need to interact with one another in order for HDR to take place. Although 
specific information on the repair pathways in oocytes is not known, spermatocytes undergoing 
meiosis have been extensively investigated by Enguita-Marruedo et al. (2019). They showed that 
from leptotene up to mid-pachytene, HDR is the preferred method of DNA repair, likely to facilitate 
crossover between homologous chromosomes.151 Then from mid-pachytene to late-diplotene NHEJ 
and HDR were both acting with NHEJ outcompeting HDR early on in late-pachytene.151 HDR 
pathways again became dominant closer towards the late-diplotene stage where NHEJ was 
downregulated.151 So, although we can’t definitively claim these processes occur in an identical 
fashion in oocytes, it is a reasonable assumption and would mean that for the majority of those first 
⁓25.5 days of Vasa expression, the oocytes are in a cellular state more favourable to homing. 
Another important point to consider when comparing Vasa-Cas9 and Vasa-Cas12a mice to those 
used in Grunwald et al. (2019) is that for the latter, a Vasa-Cre gene was used to irreversibly activate 
ubiquitous expression of Cas9 by the CAG promoter. This likely lead to slightly delayed expression 
compared to Vasa-Cas9 and probably much higher expression levels. Even considering this, they did 
not see an impressive homing rate in females compared to the insect gene drives. Lacking further 
data, it is isn’t possible to know what stages of meiosis I that the majority of Cas9-induced cleavage 
took place and whether that was a time point more conducive to NHEJ or HDR as discussed above. 
All this together points to the conclusion that Vasa is simply not a good promoter for a mouse gene 
drive. It is either not active at the optimum time and/or not enough Cas9 is produced to 
substantially promote HDR. In addition, the germ cell development state is vastly different between 
males and females when it is turned on. So ultimately there needs to be better control of Cas9 
expression and it needs to be more tightly linked to the cell cycle or the HDR pathways instead of 
tissue type, allowing for expression only when the homologous chromosomes are lined up and in an 
ideal state for HDR. 
11.2.2 Cas12a 
With the low rate of indel formation in both sexes induced by Vasa-Cas12a-A and Vasa-Cas12a-C, 
should future gene drives be developed with Cas12a? Cas12a generates a staggered break that puts 
the DNA in a potentially favourable state for non-NHEJ repair pathways28 and it is critical to avoid all 
types of error-prone repair, with NHEJ being the major error-prone repair pathway. Considering this, 
Cas12a has potential to function as an optimal gene drive. However, at this stage the data to support 
this is indirect and Cas12a has not yet been used for any gene drive system so a lot more preliminary 
work needs to be done before anything more conclusive can be stated. 
The Cas12a system itself needs improvement from what was presented in this thesis. The key 
outcome needs to be an increase in the cleavage efficiency of the Cas12a/gRNA RNP which needs to 
be addressed by looking at both components of the complex. Firstly, the expression level of Cas12a 
needs to be increased, perhaps initially by a similar strategy as demonstrated by Grunwald et al. 
(2019) where a germline promoter drives the expression of Cre to activate a CAG-Cas12a cassette. 
This would provide a simple test of whether Cas12a is more likely to induce homing compared to 
Cas9 without having to consider more critical aspects such as the particular germline promoter used. 
The gRNA is the other component of the RNP that needs to be investigated. As discussed in section 
10.4.2.3, the U6 terminator for the gRNA does not cleanly terminate transcription which leads to a 




away from the reliance on the poly-T terminator sequence and changing to something else such as a 
self-cleaving HDV which can cleanly remove the trailing nucleotides on the gRNA. 
11.3 FUTURE DIRECTIONS 
There are many future avenues of research in the gene drive field and a lot more work needs to be 
done, especially in mice and other vertebrates where high levels of homing have yet to be seen. 
Improvements or changes to most aspects of the system need to be investigated, although as 
discussed in section 11.1, zygotic homing doesn’t appear to offer much promise. 
Considering that we already know homing can occur with Cas9 in mice,108 future experiments 
perhaps should focus on improving this via selection of different promoters until a reasonably high 
level of homing can be seen and then consider further modifications. Due to the highly divergent 
timing of gametocyte development between males and females, germline promoters similar to Vasa 
which don’t have any sexual dimorphism are not going to be good candidates. Instead, a better 
strategy might be to investigate promoters that are active during meiosis, or perhaps even more 
specifically promoters that are active during the early and late stages of prophase I where we have 
evidence of HDR being the dominant repair pathway as discussed in section 11.2.1. Promoter 
candidates can be identified by looking at already characterised proteins that are expressed at these 
times and fusing their promoter regions with a Cas9 transgene. Many such candidates exist such as 
the meiotic recombinase-inducing endonuclease Spo11,152 SYCP3, a structural component of the 
synaptonemal complex,153 or the meiotic recombinase DMC1,154 all of which are active in early 
leptotene. 
It may be feasible to investigate promoters that are sex-specific instead, which might induce a higher 
level of expression at the ideal time but only in one sex. Whilst this would not be the ideal outcome, 
a gene drive that functions in only one sex is likely still better than one that doesn’t function at all. In 
addition to this, non-gene drive applications for such a system still exist, such as being able to 
generate homozygous mice with large transgenes at a greater efficiency. 
Once a relatively efficient gene drive can be constructed in mice, there are further modifications that 
could be investigated to improve the homing efficiency. A more efficient gene drive is not 
necessarily a precursor to investigating other elements however, and it may be more beneficial to 
investigate these other options before, or in tandem with investigations on alternative promoters. 
Building upon the work performed in this thesis, a functional Cas9-based gene drive may be 
improved upon by switching to Cas12a to see if that will improve homing further by reducing the 
rate of indel formation. As discussed in section 10.1.1 and 6.1.7, the staggered DSBs generated by 
Cas12a may leave the DNA in a state that does not favour NHEJ, increasing the rate of HDR. Building 
upon this idea, although Cas12a generates staggered DSBs, it does leave a 5’ overhang whereas the 
DNA resectioning that occurs leading to HDR begins by generating 3’ overhangs as discussed in 6.1.7. 
Considering this, a more promising strategy might be to use a Cas9-Nickase with multiple gRNAs 
targeting closely adjacent loci. If designed appropriately, the ssDNA cleavage by Cas9-Nickase will 
leave 3’ overhangs, perhaps better promoting the non-NHEJ repair pathways. 
Moving away from Cas9-Nickase, as discussed in section 6.6, modelling of multiplexed gRNAs 
targeting adjacent loci is a promising strategy to allow a “second chance” at homing if the second 
target site is cut after a resistance allele has already formed at the first target site. This has been 
shown to be a successful strategy when implemented in D. melanogaster, reducing resistance allele 
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